Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
AMP + diphosphate + L-methionyl-tRNAMet
ATP + L-methionine + tRNAMet
-
-
-
-
r
ATP + (S)-2-aminohex-5-enoic acid + tRNAMet
AMP + diphosphate + (S)-2-aminohex-5-enoyl-tRNAMet
ATP + (S)-2-aminohex-5-ynoic acid + tRNAMet
AMP + diphosphate + 2(S)-aminohex-5-ynoyl-tRNAMet
500fold reduced activity compared to L-methionine
-
?
ATP + azidonorleucine + tRNAMet
AMP + diphosphate + azidonorleucinyl-tRNAMet
MetRS SLL-mutant
-
-
?
ATP + azidonorleucine + tRNAMet
AMP + diphosphate + azidonorleucyl-tRNAMet
activity of mutant L13G, overview
-
-
?
ATP + L-homocysteine + tRNAMet
?
-
edition and aminoacylation by cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNA fraction from Saccharomyces cerevisiae
?
-
-
-
?
ATP + L-methionine + tRNAArg(CCU)
?
tRNA mismethionylation
-
-
?
ATP + L-methionine + tRNAAsp
AMP + diphosphate + L-methionyl-tRNAAsp
only the wild-type enzyme, not the C-terminally deleted enzyme mutant
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
ATP + L-methionine + tRNAThr(CGU)
?
tRNA mismethionylation
-
-
?
ATP + L-norleucine + tRNAMet
AMP + diphosphate + L-norleucyl-tRNAMet
ATP + L-trans-alpha-crotylglycine + tRNAMet
AMP + diphosphate + L-trans-alpha-crotylglycyl-tRNAMet
4700fold reduced activity compared to L-methionine
-
?
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
ATP + methionine + hydroxylamine
methionine hydroxamate + AMP + diphosphate
ATP + selenomethionine + tRNAMet
AMP + diphosphate + selenomethionyl-tRNAMet
CoA + L-methionine
Met-S-CoA
-
-
-
?
additional information
?
-
ATP + (S)-2-aminohex-5-enoic acid + tRNAMet
AMP + diphosphate + (S)-2-aminohex-5-enoyl-tRNAMet
-
-
-
?
ATP + (S)-2-aminohex-5-enoic acid + tRNAMet
AMP + diphosphate + (S)-2-aminohex-5-enoyl-tRNAMet
1850fold reduced activity compared to L-methionine
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the MetRS specificity for methionine and conformity with the identity rules for tRNAMet for archea/eukarya, anticodon binding site, overview
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
functional idiosyncrasies of the viral MetRS, activity with Escherichia coli native tRNAMet and initiator tRNAMet, and Saccharomyces cerevisiae native tRNAMet and initiator tRNAMet, overview, the MetRS specificity for methionine and recognition of the tRNAMet acceptor stem show conformity with the identity rules for tRNAMet for archea/eukarya, overview
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
structural basis for anticodon recognition by the enzyme, catalytic Rossmann fold domain
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
essentiality of the metS1, nonessentiality of the metS2 for vegetative growth
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
MetRS specifically binds tRNAMet and catalyzes the synthesis of methionyl-tRNAMet. The C-terminal appended domain causes a slow release of aminoacyl-tRNA and establishes a limiting step in the global aminoacylation reaction
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
also utilizes both subtypes of Escherichia coli tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
active site analysis and docking study, overview. Key residues are His53, Asp51 and Lys56 consistently forming H-bonding interactions with the carboxylic acid moiety of methionine. Ile12 forms a hydrogen bond with this moiety in different dockings and the residues Ile224, Val226 and Ala230 form a hydrophobic pocket
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
active site analysis and docking study, overview. Key residues are His53, Asp51 and Lys56 consistently forming H-bonding interactions with the carboxylic acid moiety of methionine. Ile12 forms a hydrogen bond with this moiety in different dockings and the residues Ile224, Val226 and Ala230 form a hydrophobic pocket
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
binding of L-methionine induces conformational changes of the active site of the enzyme, amino acid residues Y15 and W253 are important for the strength of binding, H301 is responsible for the specific recognition of the sulfur atom of methionine
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
covalent binding of methionine to the tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
formation of an methionine adenylate reaction intermediate
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
reduced activity with L-methionine analogues, overview, two-step reaction, the first step, the aminoacylation, is reversible, the seconde, the transfer reaction, is not
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
substrate editing mechanism, L-methionine is bound to a hydrophobic pocket formed by amino acid residues W253, Y15, A256, P257, L13, A12, I297, Y260, H301, and W305 around the side-chain
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
L-methionine and methionine analogue substrates are incorporated in proteins, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
conformation of tRNA and the recognition of anticodon by MetRS, hydrogen bonding patterns, interactions at the active site, overview
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
residues L13, P257, Y260, and H301 are involved in the Met binding site
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
two-step reaction mechanism, enzyme forms the reaction intermediate L-methionyl-adenylate, which covalently methionylates the enzyme at the epsilon-amino group of a lysine residue, inducing structural modifcation, 4.3 and 2.2 mol of Met are incorporated by 1 mol of wild-type enzyme and truncated mutant enzyme, respectively
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the C-terminal ancillary RNA-binding domain is important for activity and has dual function provided by 2 structural motifs: 1. the helix-turn-helix HTH motif, which confers rate-limiting dissociation of the aminoaclyted tRNA from the enzyme, and 2. the KGKKKK lysine-rich cluster LRC, which is probably involved in accelerating the association step of deacylated tRNA
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the nucleolar located enzyme is related to rRNA synthesis, the cytoplasmic enzyme is involved in protein biosynthesis
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
human mitochondrial wild-type and mutant mtRNAs: T5048 deletion, and T5052C or T5012A point mutations, initiator tRNA from Escherichia coli, tRNAMet from Bos taurus
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
binding structures of substrates and products, overview
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
Lupinus sp.
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
also utilizes tRNAMet from Escherichia coli
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
analysis of methionine and adenosine binding to MetRS, catalytic domain structure, overview. The KMSKS domain, residues 293-350, or stem contact fold domain, with a beta-alpha-alpha-beta-alpha topology domain, connects the catalytic domain with the anticodon domain, KMSKS domain conformation and structure, modelling, overview
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
the EMAPII-like C-terminal appendix domain provides the enzyme with non-specific tRNA binding properties, the deleted enzyme form missing this domain is therefore more specific and shows a 10fold lower Km for the tRNA substrate, enzyme is also active with tRNAMet from Saccharomyces cerevisiae
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
dimerization of the enzyme is required for affinity to tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
tRNA anticodon binding site structure
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
initiator and elongation tRNAMet, cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
covalent binding of methionine to the tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
substrates: prokaryotic, chloroplastic, cytoplasmic (initiator not non-initiator)
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-norleucine + tRNAMet
AMP + diphosphate + L-norleucyl-tRNAMet
1050fold reduced activity compared to L-methionine
-
?
ATP + L-norleucine + tRNAMet
AMP + diphosphate + L-norleucyl-tRNAMet
-
-
-
-
?
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + methionine + hydroxylamine
methionine hydroxamate + AMP + diphosphate
-
-
-
?
ATP + methionine + hydroxylamine
methionine hydroxamate + AMP + diphosphate
-
-
-
?
ATP + selenomethionine + tRNAMet
AMP + diphosphate + selenomethionyl-tRNAMet
-
-
-
-
?
ATP + selenomethionine + tRNAMet
AMP + diphosphate + selenomethionyl-tRNAMet
-
-
-
-
?
ATP + selenomethionine + tRNAMet
AMP + diphosphate + selenomethionyl-tRNAMet
-
-
-
?
additional information
?
-
-
mimivirus aminoacyl-tRNA synthetases function as regular translation enzymes in infected amoebas
-
-
?
additional information
?
-
Met-tRNA anticodon interactions with the MetRS homology model, overview
-
-
?
additional information
?
-
-
Met-tRNA anticodon interactions with the MetRS homology model, overview
-
-
?
additional information
?
-
Met-tRNA anticodon interactions with the MetRS homology model, overview
-
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
-
the enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
the enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
-
L-homocysteine is a natural competitor to L-methionine, its activation by the enzyme is prevented by a proof-reading mechanism, structural requirements are determined form the crystal structure
-
?
additional information
?
-
-
phylogenetic analysis
-
?
additional information
?
-
-
modeling of the structure of a complex consisting of MetRS, tRNA, and activated methionine, molecular dynamics simulations, evaluation of the equilibrated structure of the complex and the cross-correlations between the residues in MetRS, analysis of communication between the activation site and the anticodon recognition site, overview
-
-
?
additional information
?
-
-
no activity with L-methionyl-tRNALys
-
-
?
additional information
?
-
-
enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
-
?
additional information
?
-
the enzyme performs ATP/diphosphate exchange in absence of substrates
-
-
?
additional information
?
-
-
the enzyme performs ATP/diphosphate exchange in absence of substrates
-
-
?
additional information
?
-
Lupinus sp.
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
-
?
additional information
?
-
-
phylogenetic analysis
-
?
additional information
?
-
-
no other amino acid than methionine is activated in ATP-diphosphate exchange
-
-
?
additional information
?
-
-
enzyme forms A and B show differences in their capacity to recognize the cognate tRNAs
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
binding of the enzyme to the split 3'-half tRNA species is stronger than to that of the 5'-half species
-
-
?
additional information
?
-
-
binding of the enzyme to the split 3'-half tRNA species is stronger than to that of the 5'-half species
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
also catalyzes L-homocysteine, L-selenocysteine and norleucine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
also catalyzes L-homocysteine, L-selenocysteine and norleucine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
-
?
additional information
?
-
-
the isozymes also perform the ATP-diphosphate exchange reaction
-
?
additional information
?
-
MetRS interacts with the accessory protein Arc1p, interaction mode and structure, overview
-
-
?
additional information
?
-
-
MetRS interacts with the accessory protein Arc1p, interaction mode and structure, overview
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
also catalyzes selenomethionine- and selenoethionine-dependent ATP-diphosphate exchange
-
-
?
additional information
?
-
-
no other amino acid than methionine is activated in ATP-diphosphate exchange
-
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + azidonorleucine + tRNAMet
AMP + diphosphate + azidonorleucyl-tRNAMet
activity of mutant L13G, overview
-
-
?
ATP + L-homocysteine + tRNAMet
?
-
edition and aminoacylation by cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
additional information
?
-
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the MetRS specificity for methionine and conformity with the identity rules for tRNAMet for archea/eukarya, anticodon binding site, overview
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
essentiality of the metS1, nonessentiality of the metS2 for vegetative growth
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
MetRS specifically binds tRNAMet and catalyzes the synthesis of methionyl-tRNAMet. The C-terminal appended domain causes a slow release of aminoacyl-tRNA and establishes a limiting step in the global aminoacylation reaction
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
L-methionine and methionine analogue substrates are incorporated in proteins, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the nucleolar located enzyme is related to rRNA synthesis, the cytoplasmic enzyme is involved in protein biosynthesis
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
initiator and elongation tRNAMet, cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
additional information
?
-
-
mimivirus aminoacyl-tRNA synthetases function as regular translation enzymes in infected amoebas
-
-
?
additional information
?
-
-
L-homocysteine is a natural competitor to L-methionine, its activation by the enzyme is prevented by a proof-reading mechanism, structural requirements are determined form the crystal structure
-
?
additional information
?
-
-
phylogenetic analysis
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
phylogenetic analysis
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,3S)-3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) cyclohexanamine
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(3,5-dimethoxyphenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(4-bromophenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(4-chlorophenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(4-methoxyphenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-phenylmethanimine
-
-
(R)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) piperidin-3-amine
-
(R)-1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) pyrrolidin-3-amine
-
(S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) piperidin-3-amine
-
(S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorophenyl) piperidine-3-carboxamide
-
(S)-1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) pyrrolidin-3-amine
-
(S)-2-amino-heptanoic acid
L-methionine analogue, competitive
(S)-2-aminohex-5-enoic acid
L-methionine analogue, competitive
(S)-2-aminohex-5-ynoic acid
L-methionine analogue, competitive
(S)-3,5-dichloro-N-(1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)benzamide
-
(S)-5-chloro-2-(3-((3,5-dichlorobenzyl)oxy)piperidin-1-yl)-1H-imidazo[4,5-b]pyridine
-
1,4-anhydro-2-bromo-2,3,5-trideoxy-1-(1-fluoroethenyl)-3-methyl-5-([3-[(4-oxo-1,4-dihydroquinolin-2-yl)amino]propyl]amino)-1-thiopentitol
-
-
1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
-
1-(3-(4-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
-
1-(3-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
-
1-(3-(5-chloro-1H-benzo[d]imidazol-2-yl) piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
-
1-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
-
1-(3-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)azepan-3-amine
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)azetidin-3-amine
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-3-amine
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-4-amine
-
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[3-[(3,5-dibromobenzyl)amino]propyl]-3-phenylurea
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)-N-(3,5-dichlorobenzyl) ethanamine
-
2-(1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
2-(1H-indol-3-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(2,3-dihydroquinolin-2-yl)phenol
-
-
2-(2,4-dichlorophenyl)-6-methylquinoline
-
-
2-(2,4-dichlorophenyl)quinoline
-
-
2-(2,6-difluorophenyl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(2-bromophenyl)-6-methyl-2,3-dihydroquinoline
-
-
2-(2-butyl-4-chloro-1-(4-nitrobenzyl)-1H-imidazol-5-yl)-2,4-dihydro-1Hbenzo[d][1,3]oxazine
-
-
2-(2-butyl-4-chloro-1-(4-phenoxybenzyl)-1H-imidazol-5-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(2-butyl-4-chloro-1H-imidazol-5-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
2-(2-butyl-4-chloro-1H-imidazol-5-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(3,5-dichlorophenyl)-1-(3-(5-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethanone
-
2-(3-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]propoxy)quinazolin-4(1H)-one
-
-
2-(4-bromophenyl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-([2-[([2-[(2-fluorophenyl)methoxy]naphthalen-1-yl]methyl)amino]ethyl]amino)ethan-1-ol
-
-
2-([2-[([2-[(4-fluorophenyl)methoxy]naphthalen-1-yl]methyl)amino]ethyl]amino)ethan-1-ol
-
-
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-4H-chromen-4-one
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(2,3-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
77.9% inhibition at 50 nM
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2,4-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
87.1% inhibition at 50 nM
2-([3-[(2,5-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
93.1% inhibition at 50 nM
2-([3-[(2,6-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
51.3% inhibition at 50 nM
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2-chlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
31.8% inhibition at 50 nM
2-([3-[(3,4-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
91.7% inhibition at 50 nM
2-([3-[(3,4-dichlorobenzyl)amino]propyl]thio)quinolin-4(1H)-one
2-([3-[(3,5-dibromo-2-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(3,5-dibromo-2-methoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1H-indole-3-carbonitrile
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-6-phenylpyrimidin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-d]pyrimidin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(3,5-dichlorobenzyl)amino]propyl]amino)-4a,8a-dihydroquinolin-4(1H)-one
-
2-([3-[(3,5-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
99.2% inhibition at 50 nM
2-([3-[(3,5-difluorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
45.8% inhibition at 50 nM
2-([3-[(3,5-dimethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
35.3% inhibition at 50 nM
2-([3-[(3,5-dimethylbenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
91.1% inhibition at 50 nM
2-([3-[(3-bromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
82.7% inhibition at 50 nM
2-([3-[(3-chlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
97.3% inhibition at 50 nM
2-([3-[(3-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
19.1% inhibition at 50 nM
2-([3-[(4-chlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
52.0% inhibition at 50 nM
2-([3-[(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-chloro-4-[(4-methoxybenzyl)oxy]quinoline
2-[(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)amino]quinazolin-4(1H)-one
-
-
2-[(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)amino]quinolin-4(1H)-one
-
2-[(3-[[(4,6-dichloro-1H-indol-2-yl)methyl](methyl)amino]propyl)amino]quinazolin-4(1H)-one
-
-
2-[(3-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]propyl)amino]quinazolin-4(1H)-one
-
DDDD806905, highly potent inhibitor, competitive inhibition with respect to L-methionine
2-[(3-[[3,5-bis(trifluoromethyl)benzyl]amino]propyl)amino]quinolin-4(1H)-one
-
36.9% inhibition at 50 nM
2-[(3-[[3-(trifluoromethoxy)benzyl]amino]propyl)amino]quinolin-4(1H)-one
-
56.5% inhibition at 50 nM
2-[([2-[(4-fluorophenyl)methoxy]naphthalen-1-yl]methyl)amino]ethan-1-ol
-
-
2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-6-(trifluoromethyl)-1H-indole-4-peroxol
-
-
2-[2-allyloxy-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
-
-
2-[2-amino-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one tri(trifluoroacetic acid)
-
-
2-[2-benzyloxy-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
-
-
2-[2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-4,6-dichloro-1H-indol-1-yl]ethan-1-ol
-
-
2-[3-(3,4-dichlorobenzylamino)-1-hydroxymethylpropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-dimethylaminopropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-ethoxypropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-hydroxymethylpropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-hydroxypropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-isopropoxy-propylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-methoxymethylpropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-methoxypropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-propylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-4-hydroxybutylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
-
-
2-[3-[(3,4-dichlorobenzyl)amino]propoxy]quinolin-4(1H)-one
2-[3-[bis-(3,4-dichlorobenzyl)-amino]-2-dimethylamino-propylamino]-1H-quinolin-4-one
-
-
2-[[2-([[2-(benzyloxy)naphthalen-1-yl]methyl]amino)ethyl]amino]ethan-1-ol
-
-
2-[[3-(benzylamino)propyl]amino]quinolin-4(1H)-one
-
9.0% inhibition at 50 nM
2-[[5-(3,5-dichlorophenyl)pentyl]amino]quinazolin-4(1H)-one
-
-
3,5-dichloro-N-((1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)methyl)aniline
-
3,5-dichloro-N-[3-[(4-oxo-1,4-dihydroquinazolin-2-yl)amino]propyl]benzene-1-sulfonamide
-
-
3-(1,4-dihydro-2H-3,1-benzoxazin-2-yl)-4H-1-benzopyran-4-one
-
-
3-(1H-benzimidazol-1-yl)-N-benzylpropan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(3,5-dimethoxyphenyl)methyl]propan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(4-bromophenyl)methyl]propan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(4-chlorophenyl)methyl]propan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(4-methoxyphenyl)methyl]propan-1-amine
-
-
3-(5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecan-2-yl)-4H-chromen-4-one
-
-
3-(5-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine
-
3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) cyclohexanamine
-
3-(5-chloro-3H-imidazo [4,5-b] pyridin-2-yl)-N-(3,5-dichlorobenzyl)propan-1-amine
-
3-(6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-yl)-4H-1-benzopyran-4-one
-
-
3-(6-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl) propan-1-amine
-
3-(6-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-yl)-4H-1-benzopyran-4-one
-
-
3-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-1,4-dihydronaphthalen-1-ol
3-[([3-[(4-oxo-1,4-dihydroquinolin-2-yl)amino]propyl]amino)methyl]benzonitrile
-
20.2% inhibition at 50 nM
3-[[(4-chloronaphthalen-1-yl)oxy]methyl]piperidine
-
-
4'-((2-butyl-4-chloro-5-(5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecan-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
-
-
4'-[(3-[5-[4-(hydroxymethyl)phenyl]-1-oxa-3-azaspiro[5.5]undecan-2-yl]-2,3-dihydro-1H-indol-1-yl)methyl][1,1'-biphenyl]-2-carbonitrile
-
-
4'-[[3-(1,4-dihydro-2H-3,1-benzoxazin-2-yl)-1H-indol-1-yl]methyl][1,1'-biphenyl]-2-carbonitrile
-
-
4-(1,4-dihydro-2H-3,1-benzoxazin-2-yl)phenol
-
-
4-(1H-benzimidazol-2-yl)-N-[(2-chloro-6-fluorophenyl)methyl]aniline
-
-
4-(1H-benzimidazol-2-yl)-N-[(3-chlorophenyl)methyl]aniline
-
-
4-(1H-benzimidazol-2-yl)-N-[(4-chlorophenyl)methyl]aniline
-
-
4-(5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecan-2-yl)-N,Ndimethylaniline
-
-
4-(6-chloroquinolin-2-yl)aniline
-
-
4-(7-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-yl)phenol
-
-
4-methoxybenzyloxy-quinoline
4-[(E)-[([[N-(thiophen-2-ylcarbonyl)glycyl]amino]methyl)imino]methyl]benzoic acid
-
structure molecular modeling, binding mode, detailed overview
4-[3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-2-one
-
-
4-[4-[(1H-benzimidazol-2-ylmethyl)amino]-6-(2-chloro-4-methoxyphenoxy)pyrimidin-2-yl]piperazin-2-one
-
5-(4-methoxyphenyl)-2-(2-methyl-1H-indol-3-yl)-1-oxa-3-azaspiro[5.5]undecane
-
-
5-(4-methoxyphenyl)-2-(2-phenyl-1H-indol-3-yl)-1-oxa-3-azaspiro[5.5]undecane
-
-
5-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
5-([3-[(6,8-dibromo-3,4-dihydro-2H-1-benzopyran-4-yl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
-
-
5-chloro-2-(1-(3,5-dichlorophenethyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine
-
6-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-b]pyridin-4(7H)-one
6-chloro-2-(1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
6-chloro-2-(2-phenyl-1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
6-methyl-2-(2-methyl-1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
6-methyl-2-(2-phenyl-1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
9-(3-[(E)-[(3,5-dimethoxyphenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[(E)-[(4-bromophenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[(E)-[(4-chlorophenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[(E)-[(4-methoxyphenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(3,5-dimethoxyphenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(4-bromophenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(4-chlorophenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(4-methoxyphenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-[3-(benzylamino)propyl]-9H-purin-6-amine
-
-
9-[3-[(E)-benzylideneamino]propyl]-9H-purin-6-amine
-
-
actinomycin D
-
inhibits the nucleolar located enzyme due to dependence on polymerase I
adenosine
-
maximal inhibition at MgCl2 concentration from 4.0 mM to 10 mM, effective inhibition at high concentration of diphosphate
alpha-Amanitin
-
inhibits the nucleolar located enzyme due to dependence on polymerase I
benzoic acid 1-[(3,4-dichlorobenzylamino)-methyl]-2-(4-oxo-1,4-dihydroquinolin-2-ylamino)-ethyl ester
-
-
cisplatin
-
inhibits the nucleolar located enzyme due to dependence on polymerase I
ester analogues of L-methionyl adenylate
-
overview, modeling of interaction with the active site
Ethionine
-
methionyl-tRNA formation
hydroxamate analogues of L-methionyl adenylate
-
overview, modeling of the interaction with the active site
iodoacetamide
-
10 mM, weak
isovanilloid analogues of L-methionyl adenylate
-
overview, containing ribose biooisosteres
L-6,6,6-trifluoronorleucine
L-methionine analogue, competitive
L-cis-alpha-crotylglycine
L-methionine analogue, competitive
L-methionine hydroxamate
-
substrate analogue, inhibition mechanism, no inhibition of mutant T10M
L-norleucine
L-methionine analogue, competitive
L-norvaline
L-methionine analogue, competitive
L-trans-alpha-crotylglycine
L-methionine analogue, competitive
methionine
-
selenomethionyl-tRNA formation
N-(1,4-dihydroquinolin-2-yl)-N'-(2,3,5-trichlorobenzyl)propane-1,3-diamine
N-(1H-benzimidazol-2-yl)-N'-(3,5-dichlorobenzyl)propane-1,3-diamine
-
N-(3,5-dibromobenzyl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-(3-[[(2,5-dichlorothiophen-3-yl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(2-methyl-1-benzothiophen-3-yl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-(2-hydroxyphenyl)urea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-(3-hydroxyphenyl)urea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-phenylurea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(3-cyanophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(5-chloro-2-ethoxy-3-iodophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(5-chloro-2-hydroxyphenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2,4-dibromo-6-ethoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2,4-dichloro-6-ethoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2-bromo-4-chloro-6-ethoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2-bromo-6-ethoxy-4-methoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(3,5-dibromobenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
N-[(3,5-dichlorophenyl)methyl]-3-[(4-oxo-1,4-dihydroquinazolin-2-yl)amino]propanamide
-
-
N-[(4R)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-[(4S)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-[3-([[2-(benzyloxy)-5-chloro-3-(prop-2-en-1-yl)phenyl]methyl]amino)propyl]-N'-thiophen-3-ylurea
-
N-[3-([[5-chloro-2-hydroxy-3-(prop-2-en-1-yl)phenyl]methyl]amino)propyl]-N'-thiophen-3-ylurea
-
N-[3-[(1H-benzimidazol-2-yl)amino]propyl]-3-(trifluoromethoxy)benzamide
-
-
N-[3-[([5-chloro-3-(prop-2-en-1-yl)-2-[(prop-2-en-1-yl)oxy]phenyl]methyl)amino]propyl]-N'-thiophen-3-ylurea
-
N-[[(1R)-2-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]cyclopentyl]methyl]-1H-benzimidazol-2-amine
-
-
N1-(1H-benzimidazol-2-yl)-N3-(6,8-dichloro-3,4-dihydro-2H-1-benzopyran-4-yl)propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3,5-dichloro-2-ethoxyphenyl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3,5-dichlorophenyl)methyl]propane-1,3-diamine
-
N1-(1H-benzimidazol-2-yl)-N3-[(3,6-dichloro-1H-indol-2-yl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3-bromo-2-ethoxy-5-methylphenyl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3-bromo-5-chloro-2-ethoxyphenyl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(4,6-dichloro-3-methyl-1H-indol-2-yl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(4,7-dichloro-1H-indol-2-yl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[[4,6-bis(trifluoromethyl)-1H-indol-2-yl]methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[[6-methoxy-4-(trifluoromethyl)-1H-indol-2-yl]methyl]propane-1,3-diamine
-
-
N1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N2-[(3,5-dichlorophenyl)methyl]-N1-methylethane-1,2-diamine
-
N1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N2-(3,5-dichlorobenzyl) ethane-1,2-diamine
-
N1-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
-
-
N1-(6-chloro-1H-benzo[d]imidazol-2-yl)-N2-(3,5-dichlorobenzyl)ethane-1,2-diamine
-
N1-[(3,5-dibromophenyl)methyl]-N3-(7-methoxy-1H-benzimidazol-2-yl)propane-1,3-diamine
-
-
N1-[(3,5-dichloro-4-propylphenyl)methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[(4,5-dibromo-3-methylthiophen-2-yl)methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[(4,6-dimethyl-1H-indol-2-yl)methyl]-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[(5-bromo-2-ethoxy-3-methoxyphenyl)methyl]-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[[4-bromo-5-(difluoromethyl)-3-methylthiophen-2-yl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)-2-propylpropane-1,3-diamine
-
-
N1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
NH4+
-
ATP-diphosphate exchange
p-chloromercuribenzoate
-
-
Periodate-oxidized ATP
-
-
-
Periodate-oxidized tRNA
-
-
-
RNase
-
inhibits the nucleolar located enzyme due to dependence on rRNA
-
selenomethionine
-
methionyl-tRNA formation
vanilloid analogues of L-methionyl adenylate
-
overview, containing ribose biooisosteres
[1-[(3,4-dichlorobenzylamino)-methyl]-2-(4-oxo-1,4-dihydroquinolin-2-ylamino)ethyl]-carbamic acid tert-butyl ester
-
-
[2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-4,6-dichlorophenyl]methanol
-
-
[3-(1H-benzimidazol-2-yl)piperidin-1-yl](2-methyl-1-benzofuran-5-yl)methanone
78% and 20% inhibition at 0.1 and 0.01 mM, respectively
[3-[4-(4-Methoxy-benzyloxy)-quinolin-2-ylsulfanyl]-propyl]-carbamic acid tert-butyl ester
1,10-phenanthroline
-
little or no inhibition by 1,7-phenanthroline and 4,7-phenanthroline
1,10-phenanthroline
-
complete inhibition of the cytoplasmic isozyme at 1 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.0035 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 40 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.099 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 170 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.0066 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 340 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.0035 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 18 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.0013 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 180 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is above 0.001 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 87 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.0031 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 760 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is above 0.1 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 1670 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.099 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 170 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.0059 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 850 nM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is above 0.1 mM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 70 nM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is above 0.1 mM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 680 nM
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is above 0.1 mM
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 510 nM
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 1100 nM
1-[2-(4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[3-[(3,5-dibromobenzyl)amino]propyl]-3-phenylurea
-
-
1-[3-[(3,5-dibromobenzyl)amino]propyl]-3-phenylurea
-
IC50 is 330 nM
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.027 mM
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 430 nM
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 0.0061 mM
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 810 nM
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-4H-chromen-4-one
-
-
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-4H-chromen-4-one
-
IC50 is 0.001 mM
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
-
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
IC50 is below 0.3 nM
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
-
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 9.7 nM
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 4.9 nM
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
-
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
-
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
-
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 7.0 nM
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 3.3 nM
2-([3-[(3,4-dichlorobenzyl)amino]propyl]thio)quinolin-4(1H)-one
-
-
2-([3-[(3,4-dichlorobenzyl)amino]propyl]thio)quinolin-4(1H)-one
-
IC50 is 680 nM
2-([3-[(3,5-dibromo-2-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
98.2% inhibition at 50 nM
2-([3-[(3,5-dibromo-2-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
2-([3-[(3,5-dibromo-2-methoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
95.0% inhibition at 50 nM
2-([3-[(3,5-dibromo-2-methoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one
-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one
-
IC50 is 580 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1H-indole-3-carbonitrile
-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1H-indole-3-carbonitrile
-
IC50 is 54 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-6-phenylpyrimidin-4(1H)-one
-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-6-phenylpyrimidin-4(1H)-one
-
IC50 is 0.001 mM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 8.1 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
98.8% inhibition at 50 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-d]pyrimidin-4(1H)-one
-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-d]pyrimidin-4(1H)-one
-
IC50 is 150 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 3.9 nM
2-([3-[(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 14 nM
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
-
-
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 8.2 nM
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
-
-
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 17 nM
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
-
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-chloro-4-[(4-methoxybenzyl)oxy]quinoline
-
-
2-chloro-4-[(4-methoxybenzyl)oxy]quinoline
-
-
2-[3-[(3,4-dichlorobenzyl)amino]propoxy]quinolin-4(1H)-one
-
-
2-[3-[(3,4-dichlorobenzyl)amino]propoxy]quinolin-4(1H)-one
-
IC50 is 38 nM
3-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-1,4-dihydronaphthalen-1-ol
-
-
3-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-1,4-dihydronaphthalen-1-ol
-
IC50 is 0.0018 mM
4-methoxybenzyloxy-quinoline
-
-
4-methoxybenzyloxy-quinoline
-
-
5-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
-
-
5-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
-
IC50 is 4 nM
6-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-b]pyridin-4(7H)-one
-
-
6-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-b]pyridin-4(7H)-one
-
IC50 is 6.2 nM
ATP
-
substrate inhibition
N-(1,4-dihydroquinolin-2-yl)-N'-(2,3,5-trichlorobenzyl)propane-1,3-diamine
-
-
N-(1,4-dihydroquinolin-2-yl)-N'-(2,3,5-trichlorobenzyl)propane-1,3-diamine
-
IC50 is 0.0001 mM
N-(3,5-dibromobenzyl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-(3,5-dibromobenzyl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 5.0 nM
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
-
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 11 nM
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 18 nM
N-1H-benzimidazol-2-yl-N'-(2,4-dibromo-6-ethoxybenzyl)propane-1,3-diamine
-
-
N-1H-benzimidazol-2-yl-N'-(2,4-dibromo-6-ethoxybenzyl)propane-1,3-diamine
-
IC50 is 17 nM
N-1H-benzimidazol-2-yl-N'-(2,4-dichloro-6-ethoxybenzyl)propane-1,3-diamine
-
-
N-1H-benzimidazol-2-yl-N'-(2,4-dichloro-6-ethoxybenzyl)propane-1,3-diamine
-
IC50 is below 3 nM
N-1H-benzimidazol-2-yl-N'-(2-bromo-4-chloro-6-ethoxybenzyl)propane-1,3-diamine
-
-
N-1H-benzimidazol-2-yl-N'-(2-bromo-4-chloro-6-ethoxybenzyl)propane-1,3-diamine
-
IC50 is 3.8 nM
N-1H-benzimidazol-2-yl-N'-(2-bromo-6-ethoxy-4-methoxybenzyl)propane-1,3-diamine
-
-
N-1H-benzimidazol-2-yl-N'-(2-bromo-6-ethoxy-4-methoxybenzyl)propane-1,3-diamine
-
IC50 is 17 nM
N-1H-benzimidazol-2-yl-N'-(3,5-dibromobenzyl)propane-1,3-diamine
-
-
N-1H-benzimidazol-2-yl-N'-(3,5-dibromobenzyl)propane-1,3-diamine
-
IC50 is 29 nM
N-1H-benzimidazol-2-yl-N'-(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
-
-
N-1H-benzimidazol-2-yl-N'-(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
-
IC50 is 14 nM
N-1H-benzimidazol-2-yl-N'-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
-
-
N-1H-benzimidazol-2-yl-N'-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
-
IC50 is 16 nM
N-[(4R)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-[(4R)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 6.3 nM
N-[(4S)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-[(4S)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 48 nM
REP3123
-
active against a collection of 108 clinical isolates of Clostridium difficile and against epidemic, moxifloxacin-resistant BI/NAP1/027 strains
REP3123
a selective and potent competitive, versus methionine not ATP, MetRS inhibitor, that strongly binds at the active site, docking study
REP8839
-
-
[3-[4-(4-Methoxy-benzyloxy)-quinolin-2-ylsulfanyl]-propyl]-carbamic acid tert-butyl ester
-
-
[3-[4-(4-Methoxy-benzyloxy)-quinolin-2-ylsulfanyl]-propyl]-carbamic acid tert-butyl ester
-
-
additional information
MetRS drug design and homology modelling, overview
-
additional information
-
MetRS drug design and homology modelling, overview
-
additional information
-
structure-activity relationships of inhibitor derived from an oxazolone-dipeptide scaffold
-
additional information
-
antibacterial potency of the inhibitors, structure-activity relationships, inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
large scale MetRS inhibitor screening, diverse compounds, overview
-
additional information
-
structure-activity relationships of inhibitor derived from an oxazolone-dipeptide scaffold
-
additional information
-
antibacterial potency of the inhibitors, structure-activity relationships, inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
in vitro minimum inhibitory concentrations of quinoline compounds with different strains of Staphylococcus aureus, structure-activity relationships
-
additional information
-
inhibitor screening, hstructures, omology modeling, molecular docking studies, and computational development of pharmacophore models, overview; inhibitor screening, structures, homology modeling, molecular docking studies, and computational development of pharmacophore models, overview
-
additional information
-
inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
a homology model of the Trypanosoma brucei MetRS based on other MetRS structures is used to model binding of lead diaryl diamine compounds in the design and development of selective parasite MetRS inhibitors for treatment of African trypanosomiasis, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
15.68
(S)-2-aminohex-5-enoic acid
ATP-diphosphate exchange reaction, pH 7.6
2.42
(S)-2-aminohex-5-ynoic acid
ATP-diphosphate exchange reaction, pH 7.6
0.00303 - 0.04183
L-methionyl-tRNAMet
4.12
L-norleucine
ATP-diphosphate exchange reaction, pH 7.6
4.56
L-trans-alpha-crotylglycine
ATP-diphosphate exchange reaction, pH 7.6
0.038 - 0.31
selenomethionine
0.0007 - 0.00075
tRNA fraction from Saccharomyces cerevisiae
-
additional information
additional information
-
0.029
ATP
mutant D666A, pH and temperature not specified in the publication
0.037
ATP
-
at pH 8.0 and 25°C
0.085
ATP
pH 8.2, 37°C, recombinant enzyme
0.375
ATP
-
wild-type, first step of reaction, methionyl-adenylate formation
0.41
ATP
-
strain 547, ATP-diphosphate exchange
0.44
ATP
-
mutant G54S, first step of reaction, methionyl-adenylate formation
0.475
ATP
-
mutant H101N/G213C, first step of reaction, methionyl-adenylate formation
0.5
ATP
-
mutant G54S, ATP:diphosphate exchange reaction
0.5
ATP
-
wild-type, ATP:diphosphate exchange reaction
0.55
ATP
-
ATP-diphosphate exchange
0.595
ATP
-
mutant L213W, ATP:diphosphate exchange reaction
0.65
ATP
-
mutant V108M, ATP:diphosphate exchange reaction
0.7
ATP
-
mutant H101D, first step of reaction, methionyl-adenylate formation
0.75
ATP
-
mutant G223C, ATP:diphosphate exchange reaction
0.76
ATP
-
mutant G54A/A64P, ATP:diphosphate exchange reaction
0.765
ATP
-
mutant I57N/G54S, ATP:diphosphate exchange reaction
0.78
ATP
-
mutant V216A, first step of reaction, methionyl-adenylate formation
0.81
ATP
-
mutant I57N/V242F, ATP:diphosphate exchange reaction
0.82
ATP
-
mutant I57N, ATP:diphosphate exchange reaction
0.85
ATP
-
mutant V216F/L203S, first step of reaction, methionyl-adenylate formation
0.98
ATP
-
mutant D229E, first step of reaction, methionyl-adenylate formation
1
ATP
-
mutant I57N, first step of reaction, methionyl-adenylate formation
1.14
ATP
-
mutant A247E, ATP:diphosphate exchange reaction
1.3
ATP
-
ATP-diphosphate exchange
1.35
ATP
-
mutant G54S/L203S, first step of reaction, methionyl-adenylate formation
1.61
ATP
-
mutant I57N/I238F, ATP:diphosphate exchange reaction
1.75
ATP
-
mutant I57N/H101N, first step of reaction, methionyl-adenylate formation
2.23
ATP
-
mutant I57N/A247E, ATP:diphosphate exchange reaction
7.9
ATP
-
wild-type, pH 7.5, 37°C
58
ATP
-
mutant T10M, pH 7.5, 37°C
1.2
CoA
-
methionylation reaction, cytoplasmic isozyme, pH 7.8, 25°C
6.3
CoA
-
methionylation reaction, mitochondrial isozyme, pH 7.8, 25°C
1.8
L-homocysteine
-
editing reaction, mitochondrial isozyme, pH 7.8, 25°C
3.1
L-homocysteine
-
editing reaction, cytoplasmic isozyme, pH 7.8, 25°C
0.027
L-Met
-
-
0.133
L-Met
-
ATP-diphosphate exchange, enzyme form B
0.166
L-Met
-
ATP-diphosphate exchange, enzyme form A
0.006
L-methionine
-
mutant I57N, first step of reaction, methionyl-adenylate formation
0.017
L-methionine
-
mutant V216A, first step of reaction, methionyl-adenylate formation
0.018
L-methionine
pH 8.2, 37°C, recombinant enzyme
0.02
L-methionine
-
mutant I57N/V242F, ATP:diphosphate exchange reaction
0.0243
L-methionine
ATP-diphosphate exchange reaction, pH 7.6
0.025
L-methionine
-
mutant I57N, ATP:diphosphate exchange reaction
0.025
L-methionine
-
mutant V216F/L203S, first step of reaction, methionyl-adenylate formation
0.025
L-methionine
-
wild-type, first step of reaction, methionyl-adenylate formation
0.055
L-methionine
-
mutant G54S/L203S, first step of reaction, methionyl-adenylate formation
0.064
L-methionine
mutant D666A, pH and temperature not specified in the publication
0.075
L-methionine
-
mutant G54S, ATP:diphosphate exchange reaction
0.085
L-methionine
-
mutant I57N/I238F, ATP:diphosphate exchange reaction
0.092
L-methionine
-
mutant D229E, first step of reaction, methionyl-adenylate formation
0.1
L-methionine
-
mutant L213W, ATP:diphosphate exchange reaction
0.1
L-methionine
-
wild-type, ATP:diphosphate exchange reaction
0.14
L-methionine
-
mutant V108M, ATP:diphosphate exchange reaction
0.16
L-methionine
-
mutant G54S, first step of reaction, methionyl-adenylate formation
0.173
L-methionine
-
at pH 8.0 and 25°C
0.19
L-methionine
-
mutant I57N/H101N, first step of reaction, methionyl-adenylate formation
0.22
L-methionine
-
mutant A247E, ATP:diphosphate exchange reaction
0.25
L-methionine
-
mutant I57N/A247E, ATP:diphosphate exchange reaction
0.36
L-methionine
-
mutant I57N/G54S, ATP:diphosphate exchange reaction
0.68
L-methionine
-
mutant G223C, ATP:diphosphate exchange reaction
1.07
L-methionine
-
mutant G54A/A64P, ATP:diphosphate exchange reaction
1.55
L-methionine
-
mutant H101N/G213C, first step of reaction, methionyl-adenylate formation
7.9
L-methionine
-
wild-type, pH 7.5, 37°C
14.8
L-methionine
-
mutant H101D, first step of reaction, methionyl-adenylate formation
58
L-methionine
-
mutant T10M, pH 7.5, 37°C
0.00303
L-methionyl-tRNAMet
-
wild type enzyme, at pH 7.4 and 37°C
0.00796
L-methionyl-tRNAMet
-
mutant enzyme S209A/S825A, at pH 7.4 and 37°C
0.04183
L-methionyl-tRNAMet
-
mutant enzyme S209D/S825D, at pH 7.4 and 37°C
0.005
Met
-
-
0.015
Met
Lupinus sp.
-
-
0.018
Met
-
ligase A and B
0.02
Met
-
strain 547, ATP-diphosphate exchange
0.022
Met
-
methionine-dependent ATP-diphosphate exchange
0.032
Met
-
methionine-dependent ATP-diphosphate exchange
0.078
Met
-
wild-type enzyme
0.48 - 1.63
Met
-
Km-values of various mutant strains
0.383
norleucine
-
-
0.038
selenomethionine
-
selenomethionine-dependent ATP-diphosphate exchange
0.31
selenomethionine
-
-
0.0007
tRNA fraction from Saccharomyces cerevisiae
pH 7.5, 25°C, wild-type enzyme
-
0.00075
tRNA fraction from Saccharomyces cerevisiae
pH 7.5, 25°C, truncated mutant
-
0.00015
tRNAMet
pH 8.2, 37°C, mitochondrial tRNAMet from Bos taurus, recombinant enzyme
0.00016
tRNAMet
pH 8.2, 37°C, human mitochondrial wild-type tRNAMet, recombinant enzyme
0.00025
tRNAMet
Lupinus sp.
-
-
0.00027
tRNAMet
-
mutant G54S, aminoacylation reaction
0.0004
tRNAMet
-
recombinant mitochondrial isozyme as GST-fusion protein, pH 7.8, 25°C
0.00041
tRNAMet
-
mutant I57N/G54S, aminoacylation reaction
0.00045
tRNAMet
-
mutant I57N/A247E, aminoacylation reaction
0.00055
tRNAMet
-
wild-type, second step of reaction, tRNA aminoacylation
0.00057
tRNAMet
-
mutant G54A/A64P, aminoacylation reaction
0.00064
tRNAMet
-
mutant G54S/L203S, second step of reaction, tRNA aminoacylation
0.00065
tRNAMet
-
mutant D229E, second step of reaction, tRNA aminoacylation
0.00066
tRNAMet
in vitro synthesized tRNAMet from Saccharomyces cerevisiae, pH 7.5, 25°C, wild-type enzyme
0.0008
tRNAMet
-
mutant V216A, second step of reaction, tRNA aminoacylation
0.00089
tRNAMet
-
mutant I57N/I238F, aminoacylation reaction
0.0009
tRNAMet
-
wild-type enzyme
0.00093
tRNAMet
-
mutant I57N, aminoacylation reaction
0.00096
tRNAMet
-
mutant V216F/L203S, second step of reaction, tRNA aminoacylation
0.001
tRNAMet
-
wild-type, aminoacylation reaction
0.00102
tRNAMet
-
mutant G54S, second step of reaction, tRNA aminoacylation
0.00121
tRNAMet
-
mutant I57N/H101N, second step of reaction, tRNA aminoacylation
0.0013
tRNAMet
-
mutant A247E, aminoacylation reaction
0.0017
tRNAMet
-
mutant L213W, aminoacylation reaction
0.0021
tRNAMet
pH 8.2, 37°C, initiator tRNA from Escherichia coli, recombinant enzyme
0.0022
tRNAMet
-
C-terminal extension, pH 7.5, 25°C
0.0025
tRNAMet
-
mutant G223C, aminoacylation reaction
0.0026
tRNAMet
-
mutant I57N, second step of reaction, tRNA aminoacylation
0.0032
tRNAMet
-
substrate from Escherichia coli, 37°C
0.0032
tRNAMet
-
mutant V108M, aminoacylation reaction
0.0033
tRNAMet
-
mutant K863A, pH 7.5, 25°C
0.0035
tRNAMet
-
wild-type enzyme, pH 7.5, 25°C
0.0039
tRNAMet
-
pH 7.5, 25°C, wild-type enzyme
0.0039
tRNAMet
-
wild-type enzyme in the multi-enzyme complex and mutant K866A, pH 7.5, 25°C
0.0044
tRNAMet
-
aminoacylation reaction, wild-type
0.0057
tRNAMet
-
mutant R857A, pH 7.5, 25°C
0.0058
tRNAMet
-
aminoacylation reaction, C-terminally truncated mutant
0.006
tRNAMet
-
pH 7.5, 25°C, mutant D369K/K295D
0.0064
tRNAMet
-
aminoacylation reaction, mutant D666A
0.0065
tRNAMet
in vitro synthesized tRNAMet from Saccharomyces cerevisiae, pH 7.5, 25°C, truncated mutant
0.0087
tRNAMet
-
aminoacylation reaction, mutant M665
0.009
tRNAMet
-
recombinant cytoplasmic isozyme, pH 7.8, 25°C
0.01
tRNAMet
-
mutant I57N/V242F, aminoacylation reaction
0.0102
tRNAMet
-
pH 7.5, 25°C, mutant KA295V
0.015
tRNAMet
-
recombinant cytoplasmic isozyme as GST-fusion protein, pH 7.8, 25°C
0.0163
tRNAMet
-
mutant K880A, pH 7.5, 25°C
0.0172
tRNAMet
-
mutant K860A, pH 7.5, 25°C
0.0177
tRNAMet
-
pH 7.5, 25°C, mutant K295V
0.018
tRNAMet
-
pH 7.5, 25°C, mutant D369A
0.02
tRNAMet
-
ATP-diphosphate exchange reaction, wild-type
0.022
tRNAMet
-
ATP-diphosphate exchange reaction, C-terminally truncated mutant
0.026
tRNAMet
-
pH 7.5, 25°C, mutant D369N
0.029
tRNAMet
-
ATP-diphosphate exchange reaction, mutant D666A
0.032
tRNAMet
-
catalytic domain, pH 7.5, 25°C
0.034
tRNAMet
-
ATP-diphosphate exchange reaction, mutant M665
1
tRNAMet
-
recombinant C-terminally truncated enzyme, 37°C
additional information
additional information
-
Km-values of mutant enzymes in aminoacylation
-
additional information
additional information
-
Km-values of mutant enzymes in ATP-diphosphate exchange reaction
-
additional information
additional information
-
dissociation constants for wild-type and mutant enzymes
-
additional information
additional information
-
kinetics with Escherichia coli native tRNAMet and initiator tRNAMet, and Saccharomyces cerevisiae native tRNAMet and initiator tRNAMet, overview
-
additional information
additional information
-
steady-state kinetic parameters for tRNAMet aminoacylation and for MetRS-catalyzed diphosphate exchange of wild-type enzyme and mutants, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.35
(S)-2-aminohex-5-enoic acid
ATP-diphosphate exchange reaction, pH 7.6
2.6
(S)-2-aminohex-5-ynoic acid
ATP-diphosphate exchange reaction, pH 7.6
0.5 - 6.08
L-homocysteine
0.011 - 0.157
L-methionyl-tRNAMet
2.15
L-norleucine
ATP-diphosphate exchange reaction, pH 7.6
1.82 - 2.94
L-trans-alpha-crotylglycine
0.26 - 6.08
tRNA fraction from Saccharomyces cerevisiae
-
additional information
additional information
-
0.033
ATP
pH 8.2, 37°C, recombinant enzyme
3.4
ATP
-
mutant T10M, pH 7.5, 37°C
5.6
ATP
-
wild-type, pH 7.5, 37°C
23
ATP
mutant D666A, pH and temperature not specified in the publication
0.7
CoA
-
methionylation reaction, cytoplasmic isozyme, pH 7.8, 25°C
1.6
CoA
-
methionylation reaction, mitochondrial isozyme, pH 7.8, 25°C
0.5
L-homocysteine
-
editing reaction, mitochondrial isozyme, pH 7.8, 25°C
0.69
L-homocysteine
-
editing reaction, cytoplasmic isozyme, pH 7.8, 25°C
6.08
L-homocysteine
-
editing reaction, cytoplasmic isozyme, pH 7.8, 25°C
2.94
L-Met
-
ATP-diphosphate exchange, enzyme form A
3.13
L-Met
-
ATP-diphosphate exchange, enzyme form B
0.41
L-methionine
pH 8.2, 37°C, recombinant enzyme
1
L-methionine
-
mutant G54A/A64P, ATP:diphosphate exchange reaction
3.1
L-methionine
mutant D666A, pH and temperature not specified in the publication
3.4
L-methionine
-
mutant T10M, pH 7.5, 37°C
4
L-methionine
-
mutant G54S, first step of reaction, methionyl-adenylate formation
5
L-methionine
-
mutant G54S, ATP:diphosphate exchange reaction
5.6
L-methionine
-
wild-type, pH 7.5, 37°C
6
L-methionine
-
mutant I57N/G54S, ATP:diphosphate exchange reaction
6
L-methionine
-
mutant I57N/H101N, first step of reaction, methionyl-adenylate formation
8
L-methionine
-
mutant H101N/G213C, first step of reaction, methionyl-adenylate formation
10
L-methionine
-
mutant G223C, ATP:diphosphate exchange reaction
10
L-methionine
-
mutant L213W, ATP:diphosphate exchange reaction
11
L-methionine
-
mutant A247E, ATP:diphosphate exchange reaction
11
L-methionine
-
mutant I57N/A247E, ATP:diphosphate exchange reaction
13
L-methionine
-
mutant I57N/I238F, ATP:diphosphate exchange reaction
13.3
L-methionine
ATP-diphosphate exchange reaction, pH 7.6
14
L-methionine
-
mutant I57N, ATP:diphosphate exchange reaction
14
L-methionine
-
mutant I57N/V242F, ATP:diphosphate exchange reaction
15
L-methionine
-
mutant G54S/L203S, first step of reaction, methionyl-adenylate formation
15
L-methionine
-
mutant H101D, first step of reaction, methionyl-adenylate formation
15
L-methionine
-
mutant I57N, first step of reaction, methionyl-adenylate formation
15
L-methionine
-
mutant V108M, ATP:diphosphate exchange reaction
23
L-methionine
-
wild-type, first step of reaction, methionyl-adenylate formation
25
L-methionine
-
mutant V216A, first step of reaction, methionyl-adenylate formation
25
L-methionine
-
mutant V216F/L203S, first step of reaction, methionyl-adenylate formation
25
L-methionine
-
wild-type, ATP:diphosphate exchange reaction
33
L-methionine
-
mutant D229E, first step of reaction, methionyl-adenylate formation
0.011
L-methionyl-tRNAMet
-
mutant enzyme S209A/S825A, at pH 7.4 and 37°C
0.127
L-methionyl-tRNAMet
-
mutant enzyme S209D/S825D, at pH 7.4 and 37°C
0.157
L-methionyl-tRNAMet
-
wild type enzyme, at pH 7.4 and 37°C
1.82
L-trans-alpha-crotylglycine
ATP-diphosphate exchange reaction, pH 7.6
2.94
L-trans-alpha-crotylglycine
ATP-diphosphate exchange reaction, pH 7.6
0.26
tRNA fraction from Saccharomyces cerevisiae
pH 7.5, 25°C, truncated mutant
-
0.53
tRNA fraction from Saccharomyces cerevisiae
pH 7.5, 25°C, wild-type enzyme
-
6.08
tRNA fraction from Saccharomyces cerevisiae
pH 7.5, 25°C, wild-type enzyme
-
0.001
tRNAMet
-
mutant G54A/A64P, aminoacylation reaction
0.002
tRNAMet
-
mutant I57N/G54S, aminoacylation reaction
0.006
tRNAMet
-
mutant V216F/L203S, second step of reaction, tRNA aminoacylation
0.008
tRNAMet
-
mutant I57N/A247E, aminoacylation reaction
0.009
tRNAMet
-
mutant G54S, aminoacylation reaction
0.01
tRNAMet
-
mutant G54S, second step of reaction, tRNA aminoacylation
0.011
tRNAMet
-
mutant G54S/L203S, second step of reaction, tRNA aminoacylation
0.013
tRNAMet
-
mutant I57N/H101N, second step of reaction, tRNA aminoacylation
0.017
tRNAMet
-
mutant I57N, second step of reaction, tRNA aminoacylation
0.019
tRNAMet
pH 8.2, 37°C, mitochondrial tRNAMet from Bos taurus, recombinant enzyme
0.021
tRNAMet
pH 8.2, 37°C, human mitochondrial wild-type tRNAMet, recombinant enzyme
0.023
tRNAMet
-
mutant D229E, second step of reaction, tRNA aminoacylation
0.023
tRNAMet
-
mutant I57N, aminoacylation reaction
0.037
tRNAMet
-
mutant G223C, aminoacylation reaction
0.037
tRNAMet
-
pH 7.5, 25°C, mutant D369A
0.042
tRNAMet
-
pH 7.5, 25°C, mutant KA295V
0.05
tRNAMet
-
pH 7.5, 25°C, mutant D369K/K295D
0.055
tRNAMet
-
mutant V216A, second step of reaction, tRNA aminoacylation
0.057
tRNAMet
-
mutant A247E, aminoacylation reaction
0.066
tRNAMet
-
mutant I57N/I238F, aminoacylation reaction
0.08
tRNAMet
-
wild-type, second step of reaction, tRNA aminoacylation
0.09
tRNAMet
-
C-terminal extension, pH 7.5, 25°C
0.11
tRNAMet
-
pH 7.5, 25°C, mutant D369N
0.124
tRNAMet
-
mutant I57N/V242F, aminoacylation reaction
0.15
tRNAMet
-
wild-type enzyme, pH 7.5, 25°C
0.2
tRNAMet
-
recombinant mitochondrial isozyme as GST-fusion protein, pH 7.8, 25°C
0.22
tRNAMet
-
mutant K863A, pH 7.5, 25°C
0.23
tRNAMet
-
mutant K866A, pH 7.5, 25°C
0.29
tRNAMet
in vitro synthesized tRNAMet from Saccharomyces cerevisiae, pH 7.5, 25°C, wild-type enzyme
0.3
tRNAMet
-
pH 7.5, 25°C, mutant K295V
0.36
tRNAMet
in vitro synthesized tRNAMet from Saccharomyces cerevisiae, pH 7.5, 25°C, truncated mutant
0.46
tRNAMet
-
wild-type enzyme in the multi-enzyme complex, pH 7.5, 25°C
0.47
tRNAMet
-
mutant R857A, pH 7.5, 25°C
0.49
tRNAMet
-
wild-type, aminoacylation reaction
0.54
tRNAMet
-
mutant L213W, aminoacylation reaction
0.74
tRNAMet
-
mutant V108M, aminoacylation reaction
0.85
tRNAMet
-
mutant K860A, pH 7.5, 25°C
1
tRNAMet
-
pH 7.5, 25°C, wild-type enzyme
1
tRNAMet
-
recombinant cytoplasmic isozyme as GST-fusion protein, pH 7.8, 25°C
1.03
tRNAMet
-
mutant K880A, pH 7.5, 25°C
1.3
tRNAMet
-
recombinant cytoplasmic isozyme, pH 7.8, 25°C
2 - 8
tRNAMet
-
ATP-diphosphate exchange reaction, mutant M665
2.4
tRNAMet
-
catalytic domain, pH 7.5, 25°C
2.8
tRNAMet
-
aminoacylation reaction, wild-type
2.83
tRNAMet
-
substrate from Escherichia coli, 37°C
3 - 6
tRNAMet
-
substrate from Escherichia coli, 37°C
3.1
tRNAMet
-
aminoacylation reaction, mutant D666A
3.3
tRNAMet
-
wild-type enzyme
3.6
tRNAMet
-
aminoacylation reaction, C-terminally truncated mutant
4.4
tRNAMet
-
aminoacylation reaction, mutant M665
6.08
tRNAMet
-
mutant K880A, pH 7.5, 25°C
6.85
tRNAMet
-
recombinant C-terminally truncated enzyme, 37°C
11
tRNAMet
pH 8.2, 37°C, initiator tRNA from Escherichia coli, recombinant enzyme
23
tRNAMet
-
ATP-diphosphate exchange reaction, mutant D666A
42
tRNAMet
-
ATP-diphosphate exchange reaction, wild-type
47
tRNAMet
-
ATP-diphosphate exchange reaction, C-terminally truncated mutant
additional information
additional information
-
turnover numbers of mutant enzymes
-
additional information
additional information
-
turnover numbers of mutant enzymes
-
additional information
additional information
-
in ATP-diphosphate exchange reaction
-
additional information
additional information
-
in aminoacylation
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000106
(1R,3S)-3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) cyclohexanamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000192
(R)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) piperidin-3-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000696
(R)-1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) pyrrolidin-3-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.00005
(S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) piperidin-3-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.01
(S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorophenyl) piperidine-3-carboxamide
Trypanosoma brucei
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00005
(S)-1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) pyrrolidin-3-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.01
(S)-3,5-dichloro-N-(1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)benzamide
Trypanosoma brucei
pH and temperature not specified in the publication
0.000196
(S)-5-chloro-2-(3-((3,5-dichlorobenzyl)oxy)piperidin-1-yl)-1H-imidazo[4,5-b]pyridine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000155
1,4-anhydro-2-bromo-2,3,5-trideoxy-1-(1-fluoroethenyl)-3-methyl-5-([3-[(4-oxo-1,4-dihydroquinolin-2-yl)amino]propyl]amino)-1-thiopentitol
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.000288
1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
Trypanosoma brucei
pH and temperature not specified in the publication
0.000926
1-(3-(4-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
Trypanosoma brucei
pH and temperature not specified in the publication
0.000812
1-(3-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
Trypanosoma brucei
pH and temperature not specified in the publication
0.00006
1-(3-(5-chloro-1H-benzo[d]imidazol-2-yl) piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
Trypanosoma brucei
pH and temperature not specified in the publication
0.00005
1-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
Trypanosoma brucei
pH and temperature not specified in the publication
0.000138
1-(3-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
Trypanosoma brucei
pH and temperature not specified in the publication
0.000682
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)azepan-3-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.002166
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)azetidin-3-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.00005
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-3-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.00497
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-4-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.00004 - 0.0035
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00017 - 0.099
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00034 - 0.0066
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.000018 - 0.0035
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00018 - 0.0013
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.000087 - 0.001
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00076 - 0.0031
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00167 - 0.1
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00017 - 0.099
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00085 - 0.0059
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00007 - 0.1
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00068 - 0.1
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00051 - 0.1
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.0011
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 1100 nM
0.00033
1-[3-[(3,5-dibromobenzyl)amino]propyl]-3-phenylurea
Staphylococcus aureus
-
IC50 is 330 nM
0.00043 - 0.027
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.00081 - 0.0061
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
0.001054
2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)-N-(3,5-dichlorobenzyl) ethanamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000184
2-(3,5-dichlorophenyl)-1-(3-(5-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethanone
Trypanosoma brucei
pH and temperature not specified in the publication
0.000293
2-([2-[([2-[(4-fluorophenyl)methoxy]naphthalen-1-yl]methyl)amino]ethyl]amino)ethan-1-ol
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.001
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-4H-chromen-4-one
Staphylococcus aureus
-
IC50 is 0.001 mM
0.0000003
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 0.3 nM
0.0000097
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
Staphylococcus aureus
-
IC50 is 9.7 nM
0.0000049
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is 4.9 nM
0.000003
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 3 nM
0.000003
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 3 nM
0.000003
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 3 nM
0.000003
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 3 nM
0.000007
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
Staphylococcus aureus
-
IC50 is 7.0 nM
0.0000033
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is 3.3 nM
0.00068
2-([3-[(3,4-dichlorobenzyl)amino]propyl]thio)quinolin-4(1H)-one
Staphylococcus aureus
-
IC50 is 680 nM
0.000013
2-([3-[(3,5-dibromo-2-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
Trypanosoma brucei
pH and temperature not specified in the publication
0.000065
2-([3-[(3,5-dibromo-2-methoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
Trypanosoma brucei
pH and temperature not specified in the publication
0.00058
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one
Staphylococcus aureus
-
IC50 is 580 nM
0.000054
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1H-indole-3-carbonitrile
Staphylococcus aureus
-
IC50 is 54 nM
0.001
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-6-phenylpyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is 0.001 mM
0.0000081
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinazolin-4(1H)-one
Staphylococcus aureus
-
IC50 is 8.1 nM
0.000003
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 3 nM
0.00015
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is 150 nM
0.0000039
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is 3.9 nM
0.000008
2-([3-[(3,5-dichlorobenzyl)amino]propyl]amino)-4a,8a-dihydroquinolin-4(1H)-one
Trypanosoma brucei
pH and temperature not specified in the publication
0.000014
2-([3-[(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is 14 nM
0.0000082
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
Staphylococcus aureus
-
IC50 is 8.2 nM
0.000003
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 3 nM
0.000017
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
Staphylococcus aureus
-
IC50 is 17 nM
0.000003
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
Staphylococcus aureus
-
IC50 is below 3 nM
0.000006
2-[(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)amino]quinolin-4(1H)-one
Brucella melitensis
at pH 7.9 and 37°C
0.00009
2-[(3-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]propyl)amino]quinazolin-4(1H)-one
Leishmania donovani
-
at pH 8.0 and 25°C
0.1
2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-6-(trifluoromethyl)-1H-indole-4-peroxol
Leishmania donovani
-
IC50 above 0.1 mM, at pH 8.0 and 25°C
0.0000294
2-[2-allyloxy-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.000102
2-[2-amino-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one tri(trifluoroacetic acid)
Staphylococcus aureus
-
-
0.0000247
2-[2-benzyloxy-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.00038
2-[2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-4,6-dichloro-1H-indol-1-yl]ethan-1-ol
Leishmania donovani
-
at pH 8.0 and 25°C
0.0000186
2-[3-(3,4-dichlorobenzylamino)-1-hydroxymethylpropylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000396
2-[3-(3,4-dichlorobenzylamino)-2-dimethylaminopropylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000303
2-[3-(3,4-dichlorobenzylamino)-2-ethoxypropylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000119
2-[3-(3,4-dichlorobenzylamino)-2-hydroxymethylpropylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000023
2-[3-(3,4-dichlorobenzylamino)-2-hydroxypropylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.000091
2-[3-(3,4-dichlorobenzylamino)-2-isopropoxy-propylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.000015
2-[3-(3,4-dichlorobenzylamino)-2-methoxymethylpropylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000025
2-[3-(3,4-dichlorobenzylamino)-2-methoxypropylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000034
2-[3-(3,4-dichlorobenzylamino)-2-propylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000029
2-[3-(3,4-dichlorobenzylamino)-4-hydroxybutylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.0000011
2-[3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
isozyme MRSA
0.000038
2-[3-[(3,4-dichlorobenzyl)amino]propoxy]quinolin-4(1H)-one
Staphylococcus aureus
-
IC50 is 38 nM
0.000131
2-[3-[bis-(3,4-dichlorobenzyl)-amino]-2-dimethylamino-propylamino]-1H-quinolin-4-one
Staphylococcus aureus
-
-
0.00005
3,5-dichloro-N-((1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)methyl)aniline
Trypanosoma brucei
pH and temperature not specified in the publication
0.00058
3-(5-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000124
3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) cyclohexanamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.00005
3-(5-chloro-3H-imidazo [4,5-b] pyridin-2-yl)-N-(3,5-dichlorobenzyl)propan-1-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000243
3-(6-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl) propan-1-amine
Trypanosoma brucei
pH and temperature not specified in the publication
0.0018
3-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-1,4-dihydronaphthalen-1-ol
Staphylococcus aureus
-
IC50 is 0.0018 mM
0.000303
3-[[(4-chloronaphthalen-1-yl)oxy]methyl]piperidine
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.000177
4-(1H-benzimidazol-2-yl)-N-[(2-chloro-6-fluorophenyl)methyl]aniline
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.000237
4-[(E)-[([[N-(thiophen-2-ylcarbonyl)glycyl]amino]methyl)imino]methyl]benzoic acid
Escherichia coli
-
-
0.00495
4-[3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-2-one
Staphylococcus aureus
-
-
0.000043
4-[4-[(1H-benzimidazol-2-ylmethyl)amino]-6-(2-chloro-4-methoxyphenoxy)pyrimidin-2-yl]piperazin-2-one
Trypanosoma brucei
pH and temperature not specified in the publication
0.000004
5-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
Staphylococcus aureus
-
IC50 is 4 nM
0.000144
5-([3-[(6,8-dibromo-3,4-dihydro-2H-1-benzopyran-4-yl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.01
5-chloro-2-(1-(3,5-dichlorophenethyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine
Trypanosoma brucei
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.0000062
6-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-b]pyridin-4(7H)-one
Staphylococcus aureus
-
IC50 is 6.2 nM
0.074
anisomycin
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.0000694
benzoic acid 1-[(3,4-dichlorobenzylamino)-methyl]-2-(4-oxo-1,4-dihydroquinolin-2-ylamino)-ethyl ester
Staphylococcus aureus
-
-
0.0001
N-(1,4-dihydroquinolin-2-yl)-N'-(2,3,5-trichlorobenzyl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is 0.0001 mM
0.000046
N-(1H-benzimidazol-2-yl)-N'-(3,5-dichlorobenzyl)propane-1,3-diamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000005
N-(3,5-dibromobenzyl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
Staphylococcus aureus
-
IC50 is 5.0 nM
0.000324
N-(3-[[(2,5-dichlorothiophen-3-yl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.00136
N-(3-[[(2-methyl-1-benzothiophen-3-yl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000039
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-(2-hydroxyphenyl)urea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000029
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-(3-hydroxyphenyl)urea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000057
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-phenylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000028 - 0.000272
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
0.000045 - 0.001657
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
0.000019
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000096
N-(3-[[(3-cyanophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
10
N-(3-[[(5-chloro-2-ethoxy-3-iodophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Trypanosoma brucei
IC50 above 10 mM, pH and temperature not specified in the publication
0.000316
N-(3-[[(5-chloro-2-hydroxyphenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000011
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
Staphylococcus aureus
-
IC50 is 11 nM
0.000018
N-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
Staphylococcus aureus
-
IC50 is 18 nM
0.000017
N-1H-benzimidazol-2-yl-N'-(2,4-dibromo-6-ethoxybenzyl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is 17 nM
0.000003
N-1H-benzimidazol-2-yl-N'-(2,4-dichloro-6-ethoxybenzyl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is below 3 nM
0.0000038
N-1H-benzimidazol-2-yl-N'-(2-bromo-4-chloro-6-ethoxybenzyl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is 3.8 nM
0.000017
N-1H-benzimidazol-2-yl-N'-(2-bromo-6-ethoxy-4-methoxybenzyl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is 17 nM
0.000029
N-1H-benzimidazol-2-yl-N'-(3,5-dibromobenzyl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is 29 nM
0.000014
N-1H-benzimidazol-2-yl-N'-(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is 14 nM
0.000016
N-1H-benzimidazol-2-yl-N'-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
Staphylococcus aureus
-
IC50 is 16 nM
0.0000063
N-[(4R)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
Staphylococcus aureus
-
IC50 is 6.3 nM
0.000048
N-[(4S)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
Staphylococcus aureus
-
IC50 is 48 nM
0.001678
N-[3-([[2-(benzyloxy)-5-chloro-3-(prop-2-en-1-yl)phenyl]methyl]amino)propyl]-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000198
N-[3-([[5-chloro-2-hydroxy-3-(prop-2-en-1-yl)phenyl]methyl]amino)propyl]-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.1
N-[3-[(1H-benzimidazol-2-yl)amino]propyl]-3-(trifluoromethoxy)benzamide
Leishmania donovani
-
IC50 above 0.1 mM, at pH 8.0 and 25°C
0.001231
N-[3-[([5-chloro-3-(prop-2-en-1-yl)-2-[(prop-2-en-1-yl)oxy]phenyl]methyl)amino]propyl]-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.0017
N-[[(1R)-2-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]cyclopentyl]methyl]-1H-benzimidazol-2-amine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0039
N1-(1H-benzimidazol-2-yl)-N3-(6,8-dichloro-3,4-dihydro-2H-1-benzopyran-4-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0054
N1-(1H-benzimidazol-2-yl)-N3-[(3,5-dichloro-2-ethoxyphenyl)methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.014
N1-(1H-benzimidazol-2-yl)-N3-[(3,6-dichloro-1H-indol-2-yl)methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.012
N1-(1H-benzimidazol-2-yl)-N3-[(3-bromo-2-ethoxy-5-methylphenyl)methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0059
N1-(1H-benzimidazol-2-yl)-N3-[(3-bromo-5-chloro-2-ethoxyphenyl)methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0028
N1-(1H-benzimidazol-2-yl)-N3-[(4,6-dichloro-3-methyl-1H-indol-2-yl)methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.069
N1-(1H-benzimidazol-2-yl)-N3-[(4,7-dichloro-1H-indol-2-yl)methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.046
N1-(1H-benzimidazol-2-yl)-N3-[[4,6-bis(trifluoromethyl)-1H-indol-2-yl]methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0048
N1-(1H-benzimidazol-2-yl)-N3-[[6-methoxy-4-(trifluoromethyl)-1H-indol-2-yl]methyl]propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.00005
N1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N2-[(3,5-dichlorophenyl)methyl]-N1-methylethane-1,2-diamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.000085
N1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N2-(3,5-dichlorobenzyl) ethane-1,2-diamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.00017
N1-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.00005
N1-(6-chloro-1H-benzo[d]imidazol-2-yl)-N2-(3,5-dichlorobenzyl)ethane-1,2-diamine
Trypanosoma brucei
pH and temperature not specified in the publication
0.079
N1-[(3,5-dibromophenyl)methyl]-N3-(7-methoxy-1H-benzimidazol-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.044
N1-[(3,5-dichloro-4-propylphenyl)methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0021
N1-[(4,5-dibromo-3-methylthiophen-2-yl)methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0056
N1-[(4,6-dimethyl-1H-indol-2-yl)methyl]-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.037
N1-[(5-bromo-2-ethoxy-3-methoxyphenyl)methyl]-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.002
N1-[[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.0089
N1-[[4-bromo-5-(difluoromethyl)-3-methylthiophen-2-yl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.055
N1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)-2-propylpropane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.01
N1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
Leishmania donovani
-
at pH 8.0 and 25°C
0.000146
REP3123
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.000281
REP8839
Plasmodium falciparum
-
at pH 7.5 and 37°C
0.000102
[1-[(3,4-dichlorobenzylamino)-methyl]-2-(4-oxo-1,4-dihydroquinolin-2-ylamino)ethyl]-carbamic acid tert-butyl ester
Staphylococcus aureus
-
-
0.047
[2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-4,6-dichlorophenyl]methanol
Leishmania donovani
-
at pH 8.0 and 25°C
0.00004
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 40 nM
0.0035
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.0035 mM
0.00017
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 170 nM
0.099
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.099 mM
0.00034
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 340 nM
0.0066
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.0066 mM
0.000018
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 18 nM
0.0035
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.0035 mM
0.00018
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 180 nM
0.0013
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.0013 mM
0.000087
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 87 nM
0.001
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is above 0.001 mM
0.00076
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 760 nM
0.0031
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.0031 mM
0.00167
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 1670 nM
0.1
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is above 0.1 mM
0.00017
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 170 nM
0.099
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.099 mM
0.00085
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 850 nM
0.0059
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.0059 mM
0.00007
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 70 nM
0.1
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is above 0.1 mM
0.00068
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 680 nM
0.1
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is above 0.1 mM
0.00051
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 510 nM
0.1
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is above 0.1 mM
0.00043
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 430 nM
0.027
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.027 mM
0.00081
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Staphylococcus aureus
-
IC50 is 810 nM
0.0061
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
Enterococcus faecalis
-
IC50 is 0.0061 mM
0.000028
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.000272
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
Brucella melitensis
at pH 7.9 and 37°C
0.000045
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
Trypanosoma brucei
pH and temperature not specified in the publication
0.001657
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
Brucella melitensis
at pH 7.9 and 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
F316S
the mutant exhibits a significantly reduced growth rate compared with the wild type
F501L
the mutant exhibits a significantly reduced growth rate compared with the wild type
L216P
the mutant exhibits a significantly reduced growth rate compared with the wild type
P27S
the mutant exhibits a significantly reduced growth rate compared with the wild type
R424P
the mutant exhibits a significantly reduced growth rate compared with the wild type
D229E
-
spontaneous resistant mutant, first step
G213C
-
spontaneous resistant mutant, first step
G213D
-
spontaneous resistant mutant, first step
G54A
-
spontaneous resistant mutant, first step
G54C
-
spontaneous resistant mutant, first step
G54S
-
spontaneous resistant mutant, first step
G54S/L203S
-
spontaneous resistant mutant, second step
H101D
-
spontaneous resistant mutant, first step
H101L
-
spontaneous resistant mutant, first step
H101N
-
spontaneous resistant mutant, first step
H101N/G213C
-
spontaneous resistant mutant, second step
I105M/G213D
-
spontaneous resistant mutant, second step
I57N
-
spontaneous resistant mutant, first step
I57N/H101N
-
spontaneous resistant mutant, second step
T236K
-
spontaneous resistant mutant, first step
V216A
-
spontaneous resistant mutant, first step
V216F/L203S
-
spontaneous resistant mutant, second step
C477S
the mutant shows at least a 2fold increase in mismethionylation percentage compared to the wild type enzyme
D369K/K295D
-
site-directed mutagenesis in the MetRS SCF, the mutant shows reduced transfer RNA aminoacylation compared to the wild-type enzyme
D369N
-
site-directed mutagenesis in the MetRS SCF, the mutant shows reduced transfer RNA aminoacylation and 60fold loss in tRNAMet aminoacylation efficiency compared to the wild-type enzyme
D666A
-
activity is similar to the wild-type enzyme
F277L
the mutant displays at least a 6fold reduction in mismethionylation percentage compared to the wild type enzyme
G23A
-
mutant enzymes: L22A variant, G23A variant, G23P variant, H21N variant, H21Q variant, H24N variant, and H24Q variant, with reduced catalytic efficience and lowered maximal rate
G23P
-
mutant enzymes: L22A variant, G23A variant, G23P variant, H21N variant, H21Q variant, H24N variant, and H24Q variant, with reduced catalytic efficience and lowered maximal rate
H21N
-
mutant enzymes: L22A variant, G23A variant, G23P variant, H21N variant, H21Q variant, H24N variant, and H24Q variant, with reduced catalytic efficience and lowered maximal rate
H21Q
-
mutant enzymes: L22A variant, G23A variant, G23P variant, H21N variant, H21Q variant, H24N variant, and H24Q variant, with reduced catalytic efficience and lowered maximal rate
H24N
-
mutant enzymes: L22A variant, G23A variant, G23P variant, H21N variant, H21Q variant, H24N variant, and H24Q variant, with reduced catalytic efficience and lowered maximal rate
H24Q
-
mutant enzymes: L22A variant, G23A variant, G23P variant, H21N variant, H21Q variant, H24N variant, and H24Q variant, with reduced catalytic efficience and lowered maximal rate
H301L
-
saturation mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
K295A
-
site-directed mutagenesis in the MetRS SCF, the mutant shows reduced transfer RNA aminoacylation compared to the wild-type enzyme
K295V
-
site-directed mutagenesis in the MetRS SCF, the mutant shows reduced transfer RNA aminoacylation compared to the wild-type enzyme
K335Q
-
mutants produced by site-directed mutagenesis, Lys335-Gln substitution results in a complete loss of activity, similar loss of activity is observed when Lys335 is changed into alanine, glutamic acid, or arginine
L13G
saturation mutagenesis, three mutant clones from screening of a saturation mutagenesis library, the mutants are capable of incorporating the long-chain amino acid azidonorleucine into recombinant proteins with modest efficiency
L13N/Y260L/H301L
-
the mutant enzyme enables cells to use the methionine surrogate azidonorleucine in protein synthesis
L13S
-
saturation mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
L13S/Y260L/H301L
MetRS SLL-mutant with modified substrate specificity
L22A
-
mutant enzymes: L22A variant, G23A variant, G23P variant, H21N variant, H21Q variant, H24N variant, and H24Q variant, with reduced catalytic efficience and lowered maximal rate
P257X
-
saturation mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
Q211
the mutant shows at least a 2fold increase in mismethionylation percentage compared to the wild type enzyme
Q213A
the mutant shows at least a 2fold increase in mismethionylation percentage compared to the wild type enzyme
S209A/S825A
-
the mutant shows minimal phosphorylation upon incubation with extracellular signal-related kinase and leads to reduced activity compared to the wild type enzyme
S209D/S825D
-
the mutation mimicks dual phosphorylation and leads to reduced activity compared to the wild type enzyme
T10M
-
natural mutant, 5% activity compared to the wild-type, complementation of an enzyme-deficient Escherichia coli strain, no inhibition by L-methionine hydroxamate
T489A
the mutant shows at least a 2fold increase in mismethionylation percentage compared to the wild type enzyme
W221A
the mutant displays at least a 6fold reduction in mismethionylation percentage compared to the wild type enzyme
W461D
the mutant displays at least a 6fold reduction in mismethionylation percentage compared to the wild type enzyme
Y15A
-
natural mutant, very low residual activity, complementation of an enzyme-deficient Escherichia coli strain
Y260L
-
saturation mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
Y490A
the mutant shows at least a 2fold increase in mismethionylation percentage compared to the wild type enzyme
Y94H
-
natural mutant, unstable, no complementation of an enzyme-deficient Escherichia coli strain
F370L
the mutant has 18% of wild type activity
I523T
the mutant has 16% of wild type activity
K860A
-
site-directed mutagenesis, reduced activity
K863A
-
site-directed mutagenesis, reduced activity
K866A
-
site-directed mutagenesis, reduced activity
K880A
-
site-directed mutagenesis, altered kinetics
R857A
-
site-directed mutagenesis, reduced activity
S662D
-
the mutation induces a conformational change in methionyl-tRNAsynthetase and significantly reduces its interaction with aminoacyl-tRNA synthetase-interacting multifunctional protein-3. This mutant possesses significantly reduced catalytic activity because of loss of tRNAMet binding, resulting in down-regulation of global translation
D666A
the mutant enzyme behaves as monomer
A355C
-
site-directed mutagenesis, 115% activity compared to the wild-type enzyme, in vivo complementation of a deficient yeast strain
C337A/C340A
-
site-directed mutagenesis, inactive
C350A
-
site-directed mutagenesis, 1.5% activity compared to the wild-type enzyme, no in vivo complementation of a deficient yeast strain
C350A/C353A
-
site-directed mutagenesis, inactive
C353A
-
site-directed mutagenesis, catalytically inactive, no in vivo complementation of a deficient yeast strain
C367A
-
site-directed mutagenesis, catalytically inactive, no in vivo complementation of a deficient yeast strain, mutant shows a second zinc-binding knuckle structure
D348G
-
site-directed mutagenesis, 4.7% activity compared to the wild-type enzyme, in vivo complementation of a deficient yeast strain
D370A
-
site-directed mutagenesis, 8.7% activity compared to the wild-type enzyme, in vivo complementation of a deficient yeast strain
G347R
-
site-directed mutagenesis, catalytically inactive, no in vivo complementation of a deficient yeast strain
I363N
-
site-directed mutagenesis, 84% activity compared to the wild-type enzyme, in vivo complementation of a deficient yeast strain
P338I
-
site-directed mutagenesis, 74% activity compared to the wild-type enzyme, in vivo complementation of a deficient yeast strain
I57N/A247E
-
mutant MetRS
I57N/I238F
-
mutant MetRS
I57N/V242F
-
mutant MetRS
D229N
-
serial passage mutant
D229N
-
spontaneous resistant mutant, first step
A256X
-
random mutagnesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
A256X
-
random mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
D369A
-
site-directed mutagenesis in the MetRS SCF, the mutant shows reduced transfer RNA aminoacylation and 125fold loss in tRNAMet aminoacylation efficiency compared to the wild-type enzyme
D369A
the mutant displays at least a 6fold reduction in mismethionylation percentage compared to the wild type enzyme
M218A
-
random mutagnesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
M218A
-
random mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
M233I
-
random mutagnesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
M233I
-
random mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
M78L
-
random mutagnesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
M78L
-
random mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
M88F
-
random mutagnesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
M88F
-
random mutagenesis, the mutant shows altered amino acid substrate binding compared to the wild-type enzyme
additional information
-
gene replacement mutagenesis, downregulation of metS1 by its antisense construct, xylose-induced antisense expression, antisense orientation is identified for the metS1 allele, while no such orientation bias is seen for the metS2 allele, attenuation of MetS1 enzyme expression hypersensitizes Bacillus anthracis cells to a MetS-specific antimicrobial compound Rx-000019, but not to other antibiotics that affect cell wall assembly, fatty acid biosynthesis, protein translation, or DNA replication, overview
additional information
-
construction of truncated mutants lacking the tRNA-binding domain, deletion of the C-terminal tRBD of MetRS-Ce results in a 10fold increase in the kcat of Met-tRNAMet formation and a 15fold increase in KM for tRNAMe compared to the wild-type enzyme
additional information
-
mutant strains with an increased Km for methionine
additional information
-
construction of C-terminal truncated mutant, removal of beta10 strand and insertion of a stop codon at position 666, M665
additional information
-
high-throughput screening for mutant enzymes that enable residue-specific incorporation of noncanonical amino acids into the recombinant mutant enzymes in the bacterial cells, overview
additional information
-
replacement of amino acids of the MetRS SCF with portions of the structurally similar glutaminyl-tRNA synthetase, EC6.1.1.18, motif or with alanine residues. Chimeric variants retain significant tRNA methionylation activity, indicating that structural integrity of the helix-turn-strand-helix motif contributes more to RNA aminoacylation than does amino acid identity. In contrast, chimeras are significantly reduced in methionyl adenylate synthesis, suggesting a role for the SCF in formation of a structured active site domain
additional information
-
construction of a truncated enzyme form with 25% reduced activity compared to the wild-type enzyme
additional information
-
a strain carrying the MES1 structure gene on a high copy number plasmid, pFL1
additional information
-
construction of an inactive strain by gene disruption
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ogata, K.; Ohno, R.; Morioka, S.; Terao, K.
Further study on association of 5SrRNA-L5 protein complex and methionyl-tRNA to methionyl-tRNA synthetase in the macromolecular aminoacyl-tRNA synthetase complex
J. Biochem.
120
869-880
1996
Rattus norvegicus
brenda
Ogata, K.; Kurahashi, A.; Tanaka, S.; Ohsue, H.; Terao, K.
Occurence of 5SrRNA in high molecular weight complexes of aminoacyl-tRNA synthetases in a rat liver supernatant
J. Biochem.
110
1030-1036
1991
Rattus norvegicus
brenda
Ogata, K.; Kurahashi, A.; Kenmochi, N.; Terao, K.
Role of 5SrRNA as a positive effector of some aminoacyl-tRNA synthetases in macromolecular complexes, with specific reference to methionyl-tRNA synthetase
J. Biochem.
110
1037-1044
1991
Rattus norvegicus
brenda
Schmitt, E.; Panvert, M.; Blanquet, S.; Mechulam, Y.
Transition state stabilization by the `high' motif of class I aminoacyl-tRNA synthetases. The case of Escherichia coli methionyl-tRNA synthetase
Nucleic Acids Res.
23
4793-4798
1995
Escherichia coli
brenda
Meinnel, T.; Mechulam, Y.; Dardel, F.; Schmitter, J.M.; Hountondji, C.; Brunie, S.; Dessen, P.; Fayat, G.; Blanquet, S.
Methionyl-tRNA synthetase from E. coli - A review
Biochimie
72
625-632
1990
Escherichia coli
brenda
Fourmy, D.; Dardel, F.; Blanquet, S.
Methionyl-tRNA synthetase zinc binding domain
J. Mol. Biol.
231
1078-1089
1993
Escherichia coli
brenda
Brunie, S.; Zelwer, C.; Risler, J.L.
Crystallographic study at 2.5 A resolution of the interaction of methionyl-tRNA synthetase from Escherichia coli with ATP
J. Mol. Biol.
216
411-424
1990
Escherichia coli
brenda
Jakubowski, H.; Goldman, E.
Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells
FEBS Lett.
317
237-240
1993
Saccharomyces cerevisiae, Cricetulus griseus, Escherichia coli, Homo sapiens, Mus musculus
brenda
Robert-Gero, M.; Waller, J.P.
Purification of methionyl-tRNA synthetase from Escherichia coli K12 by affinity chromatography
Eur. J. Biochem.
31
315-319
1972
Escherichia coli
brenda
Lawrence, F.
Effect of adenosine on methionyl-tRNA synthetase
Eur. J. Biochem.
40
493-500
1973
Escherichia coli
brenda
Koch, G.L.E.; Bruton, C.J.
The subunit structure of methionyl-tRNA synthetase from Escherichia coli
FEBS Lett.
40
180-182
1974
Escherichia coli, Escherichia coli EM
brenda
Posorske, L.H.; Cohn, M.; Yanagisawa, N.; Auld, D.S.
Methionyl-tRNA synthetase of Escherichia coli. A zinc metalloprotein
Biochim. Biophys. Acta
576
128-133
1979
Escherichia coli
brenda
Armstrong, J.B.; Fairfield, J.A.
A new method for the isolation of methionyl transfer synthetase mutants from Escherichia coli
Can. J. Microbiol.
21
754-758
1975
Escherichia coli
brenda
Chazal, Ph.; Thomes, J.C.; Julien, R.
Methionine-tRNA-ligase from wheat germ. Purification and properties
FEBS Lett.
56
268-272
1975
Triticum aestivum
brenda
Zelwer, C.; Risler, J.L.; Monteilhet, C.
A low-resolution model of crystalline methionyl-transfer RNA synthetase from Escherichia coli
J. Mol. Biol.
102
93-101
1976
Escherichia coli
brenda
Deobagkar, D.N.; Gopinathan, K.P.
Two forms of methionyl-tranfer RNA synthetase from Mycobacterium smegmatis
Biochem. Biophys. Res. Commun.
71
939-951
1976
Mycolicibacterium smegmatis
brenda
Burnell, J.N.; Whatley, F.R.
Sulphur metabolism in Paracoccus denitrificans. Purification, properties and regulation of cysteinyl- and methionyl-tRNA synthetase
Biochim. Biophys. Acta
481
266-278
1977
Paracoccus denitrificans, Paracoccus denitrificans 8944
brenda
Rosa, M.D.; Sigler, P.B.
Isolation and characterization of two methionine:tRNA ligases from wheat germ
Eur. J. Biochem.
78
141-151
1977
Triticum aestivum
brenda
Dickman, S.R.; Boll, D.J.
Differential purification of methionine-tRNA synthetase and lysine-tRNA synthetase from rabbit liver
Biochem. Biophys. Res. Commun.
78
1191-1197
1977
Rattus norvegicus
brenda
Kellermann, O.; Viel, C.; Waller, J.P.
Methionyl-tRNA synthetase from sheep mammary gland. Purification of a fully active monomeric enzyme derived from high-molecular-weight complexes by controlled proteolysis
Eur. J. Biochem.
88
197-204
1978
Ovis aries
brenda
Kellermann, O.; Brevet, A.; Tonetti, H.; Waller, J.P.
Methionyl-tRNA synthetase from sheep liver. Purification of a fully active monomer derived from high-molecular-weight complexes by trypsin treatment
Eur. J. Biochem.
88
205-210
1978
Ovis aries
brenda
Joachimiak, A.; Barciszewski, J.; Twardowski, T.; Barciszewska, M.; Wiewiorowski, M.
Purification and properties of methionyl-tRNA synthetase from yellow lupine seeds
FEBS Lett.
93
51-54
1978
Lupinus sp.
-
brenda
Burnell, J.N.
Methionyl-tRNA synthetase from Phaseolus aureus. Purification and properties
Plant Physiol.
67
325-329
1981
Vigna radiata var. radiata
brenda
Carias, J.R.; Mouricout, M.; Julien, R.
Chloroplastic methionyl-tRNA synthetase from wheat
Biochem. Biophys. Res. Commun.
98
735-742
1981
Triticum aestivum
brenda
Zelwer, C.; Risler, J.L.; Brunie, S.
Crystal structure of Escherichia coli methionyl-tRNA synthetase at 2.5 A resolution
J. Mol. Biol.
155
63-81
1982
Escherichia coli
brenda
Kohda, D.; Yokoyama, S; Miyazawa, T.
Thermostable valyl-tRNA, isoleucyl-tRNA and methionyl-tRNA synthetases from an extreme thermophile Thermus thermophilus HB8. Protein structure and Zn2+ binding
FEBS Lett.
174
20-23
1984
Thermus thermophilus, Thermus thermophilus HB8 / ATCC 27634 / DSM 579
brenda
Kohda, D.; Yokoyama, S.; Miyazawa, T.
Functions of isolated domains of methionyl-tRNA synthetase from an extreme thermophile, Thermus thermophilus HB8
J. Biol. Chem.
262
558-563
1987
Thermus thermophilus, Thermus thermophilus HB8 / ATCC 27634 / DSM 579
brenda
Dardel, F.; Fayat, G.; Blanqauet, S.
Molecular cloning and primary structure of the Escherichia coli methionyl-tRNA synthetase gene
J. Bacteriol.
160
1115-1122
1984
Escherichia coli
brenda
Fasiolo,F.; Gibson, B.W.; Walter, P.; Chatton, B.; Biemann, K.; Boulanger, Y.
Cytoplasmic methionyl-tRNA synthetase from bakers' yeast. A monomer with a post-translationally modified N-terminus
J. Biol. Chem.
260
15571-15576
1985
Saccharomyces cerevisiae
brenda
Deniziak, M.A.; Barciszewski, J.
Methionyl-tRNA synthetase
Acta Biochim. Pol.
48
337-350
2001
Escherichia coli, Thermus thermophilus
brenda
Kaminska, M.; Shalak, V.; Mirande, M.
The appended C-domain of human methionyl-tRNA synthetase has a tRNA-sequestering function
Biochemistry
40
14309-14316
2001
Homo sapiens
brenda
Crepin, T.; Schmitt, E.; Blanquet, S.; Mechulam, Y.
Structure and function of the C-terminal domain of methionyl-tRNA synthetase
Biochemistry
41
13003-13011
2002
Escherichia coli, Pyrococcus abyssi (Q9V011), Pyrococcus abyssi
brenda
Lee, J.; Kang, S.U.; Kim, S.Y.; Kim, S.E.; Kang, M.K.; Jo, Y.J.; Kim, S.
Ester and hydroxamate analogues of methionyl and isoleucyl adenylates as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases
Bioorg. Med. Chem. Lett.
11
961-964
2001
Escherichia coli
brenda
Lee, J.; Kang, S.U.; Kim, S.Y.; Kim, S.E.; Job, Y.J.; Kim, S.
Vanilloid and isovanilloid analogues as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases
Bioorg. Med. Chem. Lett.
11
965-968
2001
Escherichia coli
brenda
Kaminska, M.; Deniziak, M.; Kerjan, P.; Barciszewski, J.; Mirande, M.
A recurrent general RNA binding domain appended to plant methionyl-tRNA synthetase acts as a cis-acting cofactor for aminoacylation
EMBO J.
19
6908-6917
2000
Oryza sativa (Q9ZTS1), Oryza sativa
brenda
Kim, S.; Jo, Y.J.; Lee, S.H.; Motegi, H.; Shiba, K.; Sassanfar, M.; Martinis, S.A.
Biochemical and phylogenetic analyses of methionyl-tRNA synthetase isolated from a pathogenic microorganism, Mycobacterium tuberculosis
FEBS Lett.
427
259-262
1998
Escherichia coli, Mycobacterium tuberculosis
brenda
Lee, S.W.; Jo, Y.J.; Kim, S.
Cloning and characterization of mitochondrial methionyl-tRNA synthetase from a pathogenic fungi Candida albicans
Gene
215
311-318
1998
Candida albicans (O74634), Candida albicans
brenda
Jo, Y.J.; Lee, S.W.; Jo, M.K.; Lee, J.W.; Kang, M.K.; Yoon, J.H.; Kim, S.
Methionine analogue probes functionally important residues in active site of methionyl-tRNA synthetase
J. Biochem. Mol. Biol.
32
547-553
1999
Escherichia coli
-
brenda
Ramesh, V.; RajBhandary, U.L.
Importance of the anticodon sequence in the aminoacylation of tRNAs by methionyl-tRNA synthetase and by valyl-tRNA synthetase in an archaebacterium
J. Biol. Chem.
276
3660-3665
2001
Haloferax volcanii, Haloferax volcanii WFD11
brenda
Ko, Y.G.; Kang, Y.S.; Kim, E.K.; Park, S.G.; Kim, S.
Nucleolar localization of human methionyl-tRNA synthetase and its role in ribosomal RNA synthesis
J. Cell Biol.
149
567-574
2000
Homo sapiens
brenda
Mechulam, Y.; Schmitt, E.; Maveyraud, L.; Zelwer, C.; Nureki, O.; Yokoyama, S.; Konno, M.; Blanquet, S.
Crystal structure of Escherichia coli methionyl-tRNA synthetase highlights species-specific features
J. Mol. Biol.
294
1287-1297
1999
Escherichia coli
brenda
Serre, L.; Verdon, G.; Choinowski, T.; Hervouet, N.; Risler, J.L.; Zelwer, C.
How methionyl-tRNA synthetase creates its amino acid recognition pocket upon L-methionine binding
J. Mol. Biol.
306
863-876
2001
Escherichia coli
brenda
Senger, B.; Despons, L.; Walter, P.; Jakubowski, H.; Fasiolo, F.
Yeast cytoplasmic and mitochondrial methionyl-tRNA synthetases: two structural frameworks for identical functions
J. Mol. Biol.
311
205-216
2001
Saccharomyces cerevisiae
brenda
Crepin, T.; Schmitt, E.; Mechulam, Y.; Sampson, P.B.; Vaughan, M.D.; Honek, J.F.; Blanquet, S.
Use of analogues of methionine and methionyl adenylate to sample conformational changes during catalysis in Escherichia coli methionyl-tRNA synthetase
J. Mol. Biol.
332
59-72
2003
Escherichia coli (P00959), Escherichia coli
brenda
Hountondji, C.; Beauvallet, C.; Pernollet, J.C.; Blanquet, S.
Enzyme-induced covalent modification of methionyl-tRNA synthetase from Bacillus stearothermophilus by methionyl-adenylate: identification of the labeled amino acid residues by matrix-assisted laser desorption-ionization mass spectrometry
J. Protein Chem.
19
563-568
2000
Geobacillus stearothermophilus
brenda
Menand, B.; Marechal-Drouard, L.; Sakamoto, W.; Dietrich, A.; Wintz, H.
A single gene of chloroplast origin codes for mitochondrial and chloroplastic methionyl-tRNA synthetase in Arabidopsis thaliana
Proc. Natl. Acad. Sci. USA
95
11014-11019
1998
Arabidopsis thaliana, Arabidopsis thaliana (O23761), Arabidopsis thaliana (Q9M2T9), Pisum sativum
brenda
Sugiura, I.; Nureki, O.; Ugaji-Yoshikawa, Y.; Kuwabara, S.; Shimada, A.; Tateno, M.; Lorber, B.; Giege, R.; Moras, D.; Yokoyama, S.; Konno, M.
The 2.0 A crystal structure of Thermus thermophilus methionyl-tRNA synthetase reveals two RNA-binding modules
Structure
8
197-208
2000
Thermus thermophilus, Thermus thermophilus HB8 / ATCC 27634 / DSM 579
brenda
Kiick, K.L.; Tirrell, D.A.
Protein Engineering by In Vivo Incorporation of Non-Natural Amino Acids: Control of Incorporation of Methionine Analogues by Methionyl-tRNA Synthetase
Tetrahedron
56
9487-9493
2000
Escherichia coli (P00959)
-
brenda
Crepin, T.; Schmitt, E.; Blanquet, S.; Mechulam, Y.
Three-dimensional structure of methionyl-tRNA synthetase from Pyrococcus abyssi
Biochemistry
43
2635-2644
2004
Pyrococcus abyssi (Q9V011), Pyrococcus abyssi
brenda
Spencer, A.C.; Heck, A.; Takeuchi, N.; Watanabe, K.; Spremulli, L.L.
Characterization of the human mitochondrial methionyl-tRNA synthetase
Biochemistry
43
9743-9754
2004
Homo sapiens (P56192), Homo sapiens
brenda
Tandon, M.; Coffen, D.L.; Gallant, P.; Keith, D.; Ashwell, M.A.
Potent and selective inhibitors of bacterial methionyl tRNA synthetase derived from an oxazolone-dipeptide scaffold
Bioorg. Med. Chem. Lett.
14
1909-1911
2004
Enterococcus faecalis, Staphylococcus aureus
brenda
Jarvest, R.L.; Armstrong, S.A.; Berge, J.M.; Brown, P.; Elder, J.S.; Brown, M.J.; Copley, R.C.; Forrest, A.K.; Hamprecht, D.W.; O'Hanlon, P.J.; Mitchell, D.J.; Rittenhouse, S.; Witty, D.R.
Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues
Bioorg. Med. Chem. Lett.
14
3937-3941
2004
Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis
brenda
Nakanishi, K.; Ogiso, Y.; Nakama, T.; Fukai, S.; Nureki, O.
Structural basis for anticodon recognition by methionyl-tRNA synthetase
Nat. Struct. Mol. Biol.
12
931-932
2005
Aquifex aeolicus
brenda
Yoo, T.H.; Tirrell, D.A.
High-throughput screening for methionyl-tRNA synthetases that enable residue-specific incorporation of noncanonical amino acids into recombinant proteins in bacterial cells
Angew. Chem.
46
5340-5343
2007
Escherichia coli
brenda
Kedar, G.C.; Brown-Driver, V.; Reyes, D.R.; Hilgers, M.T.; Stidham, M.A.; Shaw, K.J.; Finn, J.; Haselbeck, R.J.
Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis
Antimicrob. Agents Chemother.
51
1708-1718
2007
Bacillus anthracis
brenda
Farhanullah, R.J.; Kim, S.Y.; Yoon, E.J.; Choi, E.C.; Kim, S.; Kang, T.; Samrin, F.; Puri, S.; Lee, J.
Design and synthesis of quinolinones as methionyl-tRNA synthetase inhibitors
Bioorg. Med. Chem.
14
7154-7159
2006
Staphylococcus aureus
brenda
Kim, S.Y.; Lee, Y.S.; Kang, T.; Kim, S.; Lee, J.
Pharmacophore-based virtual screening: the discovery of novel methionyl-tRNA synthetase inhibitors
Bioorg. Med. Chem. Lett.
16
4898-4907
2006
Escherichia coli
brenda
Bharatham, N.; Bharatham, K.; Lee, K.W.
Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors
J. Mol. Graph. Model.
25
813-823
2007
Staphylococcus aureus
brenda
Abergel, C.; Rudinger-Thirion, J.; Giege, R.; Claverie, J.M.
Virus-encoded aminoacyl-tRNA synthetases: structural and functional characterization of mimivirus TyrRS and MetRS
J. Virol.
81
12406-12417
2007
Acanthamoeba polyphaga Mimivirus
brenda
Simader, H.; Hothorn, M.; Koehler, C.; Basquin, J.; Simos, G.; Suck, D.
Structural basis of yeast aminoacyl-tRNA synthetase complex formation revealed by crystal structures of two binary sub-complexes
Nucleic Acids Res.
34
3968-3979
2006
Saccharomyces cerevisiae (P00958), Saccharomyces cerevisiae
brenda
Link, A.J.; Vink, M.K.; Agard, N.J.; Prescher, J.A.; Bertozzi, C.R.; Tirrell, D.A.
Discovery of aminoacyl-tRNA synthetase activity through cell-surface display of noncanonical amino acids
Proc. Natl. Acad. Sci. USA
103
10180-10185
2006
Escherichia coli (P00959), Escherichia coli
brenda
Ghosh, A.; Vishveshwara, S.
A study of communication pathways in methionyl-tRNA synthetase by molecular dynamics simulations and structure network analysis
Proc. Natl. Acad. Sci. USA
104
15711-15716
2007
Escherichia coli
brenda
Farhanullah, ; Kang, T.; Yoon, E.J.; Choi, E.C.; Kim, S.; Lee, J.
2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors
Eur. J. Med. Chem.
44
239-250
2008
Staphylococcus aureus
brenda
Ingvarsson, H.; Jones, T.A.; Unge, T.
Crystallization of Mycobacterium smegmatis methionyl-tRNA synthetase in the presence of methionine and adenosine
Acta Crystallogr. Sect. F
65
618-620
2009
Mycolicibacterium smegmatis (A0R3E2), Mycolicibacterium smegmatis
brenda
Green, L.; Bullard, J.; Ribble, W.; Dean, F.; Ayers, D.; Ochsner, U.; Janjic, N.; Jarvis, T.
Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity
Antimicrob. Agents Chemother.
53
86-94
2009
Escherichia coli, Haemophilus influenzae, Homo sapiens, Staphylococcus aureus, Streptococcus pneumoniae
brenda
Critchley, I.A.; Green, L.S.; Young, C.L.; Bullard, J.M.; Evans, R.J.; Price, M.; Jarvis, T.C.; Guiles, J.W.; Janjic, N.; Ochsner, U.A.
Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
J. Antimicrob. Chemother.
63
954-963
2009
Clostridioides difficile, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Homo sapiens, Staphylococcus aureus
brenda
Ochsner, U.A.; Bell, S.J.; OLeary, A.L.; Hoang, T.; Stone, K.C.; Young, C.L.; Critchley, I.A.; Janjic, N.
Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
J. Antimicrob. Chemother.
63
964-971
2009
Clostridioides difficile
brenda
Schmitt, E.; Tanrikulu, I.C.; Yoo, T.H.; Panvert, M.; Tirrell, D.A.; Mechulam, Y.
Switching from an induced-fit to a lock-and-key mechanism in an aminoacyl-tRNA synthetase with modified specificity
J. Mol. Biol.
394
843-851
2009
Escherichia coli (P00959)
brenda
Shibata, S.; Gillespie, J.R.; Kelley, A.M.; Napuli, A.J.; Zhang, Z.; Kovzun, K.V.; Pefley, R.M.; Lam, J.; Zucker, F.H.; Van Voorhis, W.C.; Merritt, E.A.; Hol, W.G.; Verlinde, C.L.; Fan, E.; Buckner, F.S.
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei infection in mice
Antimicrob. Agents Chemother.
55
1982-1989
2011
Trypanosoma brucei
brenda
Casina, V.C.; Lobashevsky, A.A.; McKinney, W.E.; Brown, C.L.; Alexander, R.W.
Role for a conserved structural motif in assembly of a class I aminoacyl-tRNA synthetase active site
Biochemistry
50
763-769
2011
Escherichia coli
brenda
Larson, E.T.; Kim, J.E.; Zucker, F.H.; Kelley, A.; Mueller, N.; Napuli, A.J.; Verlinde, C.L.; Fan, E.; Buckner, F.S.; Van Voorhis, W.C.; Merritt, E.A.; Hol, W.G.
Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate
Biochimie
93
570-582
2011
Leishmania major
brenda
Ingvarsson, H.; Unge, T.
Flexibility and communication within the structure of the Mycobacterium smegmatis methionyl-tRNA synthetase
FEBS J.
277
3947-3962
2010
Mycolicibacterium smegmatis
brenda
Al-Moubarak, E.; Simons, C.
A homology model for Clostridium difficile methionyl tRNA synthetase: active site analysis and docking interactions
J. Mol. Model.
17
1679-1693
2010
Clostridioides difficile (Q181D9), Clostridioides difficile, Clostridioides difficile 630 (Q181D9)
brenda
Havrylenko, S.; Legouis, R.; Negrutskii, B.; Mirande, M.
Methionyl-tRNA synthetase from Caenorhabditis elegans: a specific multidomain organization for convergent functional evolution
Protein Sci.
19
2475-2484
2010
Caenorhabditis elegans
brenda
Kang, T.; Kim, G.; Park, S.G.; Jo, Y.J.
Convergent evolution of two different random RNAs for specific interaction with methionyl-tRNA synthetase
Biochem. Biophys. Res. Commun.
432
281-286
2013
Mycobacterium tuberculosis
brenda
van Meel, E.; Wegner, D.J.; Cliften, P.; Willing, M.C.; White, F.V.; Kornfeld, S.; Cole, F.S.
Rare recessive loss-of-function methionyl-tRNA synthetase mutations presenting as a multi-organ phenotype
BMC Med. Genet.
14
106
2013
Homo sapiens (P56192)
brenda
Kwon, N.H.; Kang, T.; Lee, J.Y.; Kim, H.H.; Kim, H.R.; Hong, J.; Oh, Y.S.; Han, J.M.; Ku, M.J.; Lee, S.Y.; Kim, S.
Dual role of methionyl-tRNA synthetase in the regulation of translation and tumor suppressor activity of aminoacyl-tRNA synthetase-interacting multifunctional protein-3
Proc. Natl. Acad. Sci. USA
108
19635-19640
2011
Homo sapiens
brenda
Jones, T.E.; Alexander, R.W.; Pan, T.
Misacylation of specific nonmethionyl tRNAs by a bacterial methionyl-tRNA synthetase
Proc. Natl. Acad. Sci. USA
108
6933-6938
2011
Escherichia coli (P00959), Escherichia coli
brenda
Ngo, J.T.; Schuman, E.M.; Tirrell, D.A.
Mutant methionyl-tRNA synthetase from bacteria enables site-selective N-terminal labeling of proteins expressed in mammalian cells
Proc. Natl. Acad. Sci. USA
110
4992-4997
2013
Escherichia coli
brenda
Koh, C.Y.; Kim, J.E.; Shibata, S.; Ranade, R.M.; Yu, M.; Liu, J.; Gillespie, J.R.; Buckner, F.S.; Verlinde, C.L.; Fan, E.; Hol, W.G.
Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection
Structure
20
1681-1691
2012
Trypanosoma brucei (Q38C91), Trypanosoma brucei
brenda
Torrie, L.S.; Brand, S.; Robinson, D.A.; Ko, E.J.; Stojanovski, L.; Simeons, F.R.C.; Wyllie, S.; Thomas, J.; Ellis, L.; Osuna-Cabello, M.; Epemolu, O.; Nuehs, A.; Riley, J.; MacLean, L.; Manthri, S.; Read, K.D.; Gilbert, I.H.; Fairlamb, A.H.; De Rycker, M.
Chemical validation of methionyl-tRNA synthetase as a druggable target in Leishmania donovani
ACS Infect. Dis.
3
718-727
2017
Leishmania donovani
brenda
Hussain, T.; Yogavel, M.; Sharma, A.
Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases
Antimicrob. Agents Chemother.
59
1856-1867
2015
Plasmodium falciparum
brenda
Fortowsky, G.B.; Simard, D.J.; Aboelnga, M.M.; Gauld, J.W.
Substrate-assisted and enzymatic pretransfer editing of nonstandard amino acids by methionyl-tRNA synthetase
Biochemistry
54
5757-5765
2015
Pyrococcus abyssi (Q9V011)
brenda
Kim, E.Y.; Jung, J.Y.; Kim, A.; Kim, K.; Chang, Y.S.
Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer
BMC Cancer
17
467
2017
Homo sapiens, Mus musculus
brenda
Huang, W.; Zhang, Z.; Barros-Alvarez, X.; Koh, C.Y.; Ranade, R.M.; Gillespie, J.R.; Creason, S.A.; Shibata, S.; Verlinde, C.L.M.J.; Hol, W.G.J.; Buckner, F.S.; Fan, E.
Structure-guided design of novel Trypanosoma brucei methionyl-tRNA synthetase inhibitors
Eur. J. Med. Chem.
124
1081-1092
2016
Trypanosoma brucei (Q38C91), Trypanosoma brucei, Trypanosoma brucei 927 (Q38C91)
brenda
Yi, H.; Lee, H.; Cho, K.H.; Kim, H.S.
Mutations in MetG (methionyl-tRNA synthetase) and TrmD [tRNA (guanine-N1)-methyltransferase] conferring meropenem tolerance in Burkholderia thailandensis
J. Antimicrob. Chemother.
73
332-338
2018
Burkholderia thailandensis (Q2T087), Burkholderia thailandensis
brenda
Lee, J.Y.; Kim, D.G.; Kim, B.G.; Yang, W.S.; Hong, J.; Kang, T.; Oh, Y.S.; Kim, K.R.; Han, B.W.; Hwang, B.J.; Kang, B.S.; Kang, M.S.; Kim, M.H.; Kwon, N.H.; Kim, S.
Promiscuous methionyl-tRNA synthetase mediates adaptive mistranslation to protect cells against oxidative stress
J. Cell Sci.
127
4234-4245
2014
Escherichia coli
brenda
Eissa, A.G.; Blaxland, J.A.; Williams, R.O.; Metwally, K.A.; El-Adl, S.M.; Lashine, E.L.-S.M.; Baillie, L.W.; Simons, C.
Targeting methionyl tRNA synthetase design, synthesis and antibacterial activity against Clostridium difficile of novel 3-biaryl-N-benzylpropan-1-amine derivatives
J. Enzyme Inhib. Med. Chem.
31
1694-1697
2016
Clostridioides difficile, Clostridioides difficile 1813
brenda
Suzuki, H.; Kaneko, A.; Yamamoto, T.; Nambo, M.; Hirasawa, I.; Umehara, T.; Yoshida, H.; Park, S.Y.; Tamura, K.
Binding properties of split tRNA to the C-terminal domain of methionyl-tRNA synthetase of Nanoarchaeum equitans
J. Mol. Evol.
84
267-278
2017
Nanoarchaeum equitans (Q74MZ1), Nanoarchaeum equitans
brenda
Alriyami, M.Z.; Jones, M.R.; Johnsen, R.C.; Banerjee, Y.; Baillie, D.L.
Let-65 is cytoplasmic methionyl tRNA synthetase in C. elegans
Meta Gene
2
819-830
2014
Caenorhabditis elegans, Caenorhabditis elegans N2 Bristol
brenda
Bharathkumar, H.; Mohan, C.D.; Rangappa, S.; Kang, T.; Keerthy, H.K.; Fuchs, J.E.; Kwon, N.H.; Bender, A.; Kim, S.; Basappa, S.; Rangappa, K.S.
Screening of quinoline, 1,3-benzoxazine, and 1,3-oxazine-based small molecules against isolated methionyl-tRNA synthetase and A549 and HCT116 cancer cells including an in silico binding mode analysis
Org. Biomol. Chem.
13
9381-9387
2015
Homo sapiens
brenda
Koh, C.Y.; Kim, J.E.; Wetzel, A.B.; de van der Schueren, W.J.; Shibata, S.; Ranade, R.M.; Liu, J.; Zhang, Z.; Gillespie, J.R.; Buckner, F.S.; Verlinde, C.L.; Fan, E.; Hol, W.G.
Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness
PLoS Negl. Trop. Dis.
8
e2775
2014
Trypanosoma brucei (Q38C91), Trypanosoma brucei, Trypanosoma brucei 927 (Q38C91)
brenda
Ojo, K.K.; Ranade, R.M.; Zhang, Z.; Dranow, D.M.; Myers, J.B.; Choi, R.; Nakazawa Hewitt, S.; Edwards, T.E.; Davies, D.R.; Lorimer, D.; Boyle, S.M.; Barrett, L.K.; Buckner, F.S.; Fan, E.; Van Voorhis, W.C.
Brucella melitensis methionyl-tRNA-synthetase (MetRS), a potential drug target for brucellosis
PLoS ONE
11
e0160350
2016
Brucella melitensis (Q2YQ76), Brucella melitensis, Brucella melitensis 2308 (Q2YQ76)
brenda